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ABSTRACT

CHARACTERIZATION AND DEVELOPMENT OF A STROKE-INDUCED
MODEL OF ACQUIRED EPILEPSY IN ORGANOTYPIC HIPPOCAMPAL
SLICE CULTURES: ROLE OF THE CANNABINOID CB1 RECEPTORS IN
MODULATION OF NEURONAL EXCITATION AND INHIBITION
Julie Marie Ziobro, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2010.
Director: Dr. Robert J. DeLorenzo, M.D., Ph.D., M.P.H.
George Bliley Professor of Neurology
Professor, Biochemistry, and Pharmacology and Toxicology

Stroke is the most common cause of acquired epilepsy in persons 35 and older.
The massive increase in extracellular glutamate during stroke causes a cascade of
intracellular events that can lead to cell death or the molecular changes that initiate the
development of epilepsy. In addition, many studies point to a modulatory role of the
endocannabinoid system in controlling seizures. Animal models of stroke inducedacquired epilepsy have been difficult to develop. Therefore, this dissertation was initiated
to develop an organotypic hippocampal slice culture model of acquired epilepsy and
examine the changes in distribution and function of the endogenous CB1 receptor system.
We utilized 4-aminopyridine and glutamate to induce separate excitotoxic injuries to slice
cultures. Both injuries produced significant cell death acutely following the injury. After
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a latency period, we observed a significant increase in the number of slice cultures that
displayed electrographic seizures in both injury models. Western blot analysis
demonstrated that the cannabinoid CB1 receptor protein was significantly upregulated
following injury with glutamate. Immnohistochemical studies demonstrated that this
receptor upregulation was likely specific to the glutamatergic terminals.
Electrophysiological experiments were performed to study endocannabinoid modulation
of inhibitory and excitatory signaling in the CA3 pyramidal cells. We demonstrated that
depolarization induced suppression of excitation (DSE) was enhanced in slice cultures
that had undergone glutamate injury. This indicated that the upregulation of CB1
receptors following glutamate injury was physiologically functional, as it enhanced
cannabinoid control of the excitatory signaling. These studies support the hypothesis that
there is a functional alteration of CB1 receptors in the epileptic state that acts to suppress
seizures. The development of an organotypic hippocampal slice culture model of stroke
acquired epilepsy provides a unique tool to study the neuronal plasticity changes
associated with epileptogenesis. It also provides a practical model to study
pharmacological agents that may be useful in preventing or treating epilepsy.

GENERAL INTRODUCTION

A. Epilepsy
Epilepsy is a debilitating neurological condition that affects persons worldwide. It
is one of the oldest conditions known to mankind, characterized by recurrent seizures.
The word “epilepsy” is derived from the Greek word “epilambanein” which means “to
seize or attack” (Kobau et al., 2005). Normal brain function relies on interconnected
neuronal networks in the brain to generate synchronized activities. A transformation of
otherwise normal brain rhythms may lead to epileptic seizures, resulting from sudden,
usually brief, excessive electrical discharges in neurons in different parts of the brain
(Lutz, 2004). The clinical manifestations of seizures will vary and depend on where in the
brain the disturbance first starts and how far it spreads. Symptoms such as loss of
awareness or consciousness, disturbances of movement, sensation, mood or mental
function may occur transiently (Kobau et al., 2005; Lutz, 2004).
It is estimated that epilepsy affects about 1% of the human population, with a
lifetime incidence approaching 3% (Lutz, 2004). The incidence is highest in the first year
of life and again in elderly persons. It is a disorder that affects an estimated 2.7 million
people in the United States and costs about $15.5 billion in medical costs and lost or
reduced earnings and productivity each year (Kobau et al., 2005). Each year, about
200,000 new cases of epilepsy are diagnosed in the United States. People of low
socioeconomic status, those who live in urban areas, and members of some minority
1

populations are at increased risk for epilepsy. In addition, patients with epilepsy tend to
rate their quality of life lower than people without epilepsy, reporting approximately 8
more physically and mentally unhealthy days per month than persons with no history of
epilepsy (Kobau et al., 2005). It is a truly debilitating condition that limits independence,
as most states require 6 seizure-free months before a person can obtain a driver’s license.
It also limits social interaction, as there is a lack of understanding of the disease, leading
to negative attitudes, beliefs and stigma causing discrimination in the workplace and in
schools (Kobau et al., 2005).
More than 40 recognized types of epileptic syndromes can be classified into two
categories, generalized and partial, based on excitatory activation in the brain (Lutz,
2004). Generalized epilepsies result in seizures occurring throughout the cortex because
of a generalized lowering of the seizure threshold, and are often genetically determined.
They typically involve both brain hemispheres from onset. Generalized seizures can be
further sub-classified into generalized tonic-clonic, absence, tonic, atonic, and clonic and
myoclonic seizures, based on clinical presentation (Porter and Meldrum, 2004). Tonicclonic are the most common generalized seizures, consisting of sustained contractions
(tonic) and oscillating contraction and relaxation (clonic) components (Morimoto et al.,
2004). Absence seizures represent a distinct type of generalized seizure, generated by
thalamocortical loops without a strong motor system recruitment (Elger and Schmidt,
2008; Morimoto et al., 2004). Partial seizures result from the focal point of the excitation
beginning in a localized fashion (Elger and Schmidt, 2008). Partial seizures are subclassified into simple partial and complex partial seizures, based on extent of spread. A
partial seizure may also lead to a generalized seizure, termed “partial seizure secondarily
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generalized” (Porter and Meldrum, 2004). Generalized and partial seizures are diagnosed
by the clinical presentation as well as EEG findings. The most severe type of seizure is
termed status epilepticus (SE). SE is a medical emergency that is associated with a high
morbidity and mortality. It is characterized by a seizure lasting longer than 30 minutes or
recurrent seizures without regaining consciousness for greater than 30 minutes.
Clinically, 25% of SE cases occur in patients who have been diagnosed with epilepsy. At
some point in their lives, 16% of patients with epilepsy will experience an episode of SE
(DeLorenzo, 2006), often precipitated by a change in medication or lack of adequate
blood levels of an anti-epileptic medication. Twelve to thirty percent of patients with a
new diagnosis of epilepsy first present in SE, indicating that it is often the precipitating
event to epileptogenesis (DeLorenzo et al., 2005).
Though medical science has advanced in the diagnosis and treatment of epilepsy,
the cause of the disease still remains unknown for many patients. Known causes include
traumatic brain injury, stroke, CNS infections (meningitis, encephalitis, etc.), brain
tumors, brain malformations, and febrile seizures in infancy (DeLorenzo et al., 2005). It
is still unclear how some of these initial insults can lead to epileptogenesis, the
development of epilepsy. Another portion of epilepsies are termed cryptogenic and
presumed to be genetic (Elger and Schmidt, 2008; Kobau et al., 2005) though very little
is known about the genes that underlie epileptogenesis (Elger and Schmidt, 2008).
Mutations of voltage-gated Na+, K+, and Cl- channels, as well as ligand gated GABAA
and acetylcholine channels are known to exist in idiopathic epilepsies (Elger and
Schmidt, 2008). Over 70 epilepsy susceptibility genes have been found in humans, yet
cannabinoid receptors and other components of the endogenous cannabinoid system have
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not yet been implicated as mutations in epilepsy subjects (Lutz, 2004). Seizures may also
occur due to acute and temporary conditions, such as fever, metabolic disturbance, or
alcohol withdrawal. These seizures do not lead to the diagnosis of epilepsy unless the
seizures recur in the absence of the acute and temporary condition (Elger and Schmidt,
2008; Kobau et al., 2005).The type and cause of seizures is of great importance clinically,
as it influences which types of medical interventions are most appropriate.

B. Current treatments of epilepsy
Current medical interventions include anti-epileptic drugs (AEDs), surgery, and
vagus nerve stimulation (VNS). Drugs such as phenytoin, carbamazepine, valproate, and
the barbiturates are classically used to treat partial seizures and generalized tonic-clonic
seizures. Newer drugs, such as lamotrigine, gabapentin, oxcarbazepine, topiramate,
vigabatrin, and levetiracetam are becoming more useful in industrialized countries (Porter
and Meldrum, 2004). Exact mechanisms of action are not known for all AEDs, but some
are known to act by altering Na+, K+, and Cl- conductance, membrane potentials, and the
concentrations of amino acids and the neurotransmitters norepinephrine, acetylcholine,
and GABA (Porter and Meldrum, 2004). Ethosuximide, valproic acid, and sodium
valproate are generally used in the treatment of absence seizures. Ethosuximide reduces
the low-threshold T-type Ca2+ current, seen as therapeutically relevant in thalamic
neurons, while the mechanism of action for valproic acid is poorly understood. Other
drugs useful in the management of epilepsy include the benzodiazepines, which act on
GABAA receptor-chloride ion channels, and acetazolamide, a diuretic that may act by
inducing mild acidosis in the brain (Porter and Meldrum, 2004). Though one or more
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AEDs effectively control seizures in 60-70% of persons with epilepsy, other means of
medical intervention are considered for those individuals who do not respond or cannot
tolerate AEDs.
Adjunctive resective surgery is a standard of care for a small group of properly
selected patients with drug-resistant partial epilepsy, especially mesial temporal lobe
epilepsy (Elger and Schmidt, 2008). The surgical approach chosen depends on many
considerations including the localization and the extent of the epileptogenic zone, MRI
findings, preoperative monitoring, and the risk–benefit balance of the resective surgery
itself. With surgery, 25-30% of patients are seizure free with no AEDs, while another 2530% can be seizure free with adjunctive AED therapy (Elger and Schmidt, 2008). Vagus
nerve stimulation is useful for some of the drug-resistant population with partial seizures
if surgery is not an option. Stimulating electrodes are implanted in the left vagus nerve
and the pacemaker is implanted in the chest wall or axilla. Use of this device reduces the
number of partial seizures by one-third with continued AED therapy (Elger and Schmidt,
2008). Even with these many options, 30% of patients with epilepsy do not obtain
satisfactory control of their seizures, with temporal lobe epilepsy (TLE) being the most
common and drug resistant type of partial epilepsy (Morimoto et al., 2004). This large
population clearly demonstrates the need for further exploration of other pharmacological
targets to control neuronal hyperexcitability.

C. Stroke induced acquired epilepsy
Stroke is a catastrophic event with significant morbidity and mortality. It is
estimated that there are more than 795,000 strokes per year in the United States and that
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140,000 of them result in death (Klein-Ritter, 2009). Stroke is defined by the World
Health Organization as the clinical syndrome of rapid onset of focal (or global, as in
subarachnoid hemorrhage) cerebral deficit, lasting more than 24 hours or leading to
death, with no apparent cause other than a vascular one (Warlow et al., 2003). There are
three types of stroke: ischemic, primary intracerebral hemorrhagic, and subarachnoid
hemorrhagic, with ischemic strokes accounting for about 80% of all strokes in white
populations (Warlow et al., 2003). Stroke is one of the leading causes of acquired
epilepsy (Hauser and Hesdorffer, 1990; Hauser et al., 1991), yet little is known about the
underlying basic mechanisms leading to stroke-induced epilepsy. The incidence of
developing epilepsy is highest in the first year of life and again in elderly persons. In fact,
among persons 35 and older, stroke is the most common known cause of epilepsy
(Forsgren et al., 1996). Compared to the population in the community, patients who have
had a cerebral infarct have a 17-fold greater risk of experiencing recurrent seizures (Ferro
and Pinto, 2004). As a result of the increase in the proportion of older people and the
future effects of current smoking patterns in less developed countries, it is estimated that
by 2020, stroke mortality will have almost doubled (Warlow et al., 2003). This also
provides an indication that the incidence of stroke related epilepsy will continue to rise
without continuing research efforts into prevention and treatment of this debilitating
disease.

D. Glutamate in stroke
Glutamate plays a central role in neuronal injury during an ischemic brain injury.
Focal impairment of cerebral blood flow restricts the delivery of oxygen and glucose to
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the neurons. This inhibits oxidative phosphorylation by the mitochondrial electron
transport chain and depletes the cellular stores of energy rich ATP and phosphocreatanine
(Lipton, 1999). The loss of cellular ATP causes a compensatory switch to anaerobic
metabolism, resulting in the accumulation of lactate and hydrogen ions precipitating
acidosis (Katsura et al., 1993). In addition, loss of cellular ATP impairs the energetics
required to maintain normal ionic gradients. With this energy loss, normal membrane
potential is lost and neurons depolarize, activating voltage-dependent Ca2+ channels.
This, in turn allows for the release of excitatory amino acids (particularly, glutamate) into
the extracellular space. In addition, reuptake of glutamate is impeded, as it is an energy
dependent process, further increasing the extracellular concentration of glutamate
(Dirnagl et al., 1999). The extracellular glutamate concentrations rise from micromolar to
millimolar levels from the ischemic core to the surrounding penumbra (area around the
core of the stroke). The excessive glutamate continuously acts on post-synaptic glutamate
receptors, flooding the post-synaptic neurons with Na+ and Ca2+ ions. This also allows
for the passive entry of Cl- ions, creating an osmotic gradient that leads to cell swelling
and immediate cell death. In cells that do not die in this immediate time frame, the
intracellular Ca2+ levels continue to rise with activation of NMDA receptors and
metabotropic glutamate receptors. The rise in intracellular Ca2+ is thought to initiate a
series of cytoplasmic and nuclear events that impact the development of tissue damage
(Dirnagl et al., 1999) and cause delayed neuronal cell death (see Figure 1). In cells that
survive the insult, much experimental evidence exists to suggest that the rise in
intracellular Ca2+ plays a role in the development of epilepsy (DeLorenzo et al., 2005).
Calcium is a major signaling molecule in neurons and free neuronal calcium is
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tightly regulated by various mechanisms in the cell. Brief, controlled elevations of Ca2+
are essential for neurotransmitter release and long-term potentiation. Following a CNS
injury, there is a significant elevation in intracellular Ca2+ concentrations (Raza et al.,
2004; Raza et al., 2001; Sun et al., 2004). The cells that survive these elevated Ca2+
levels continue to maintain elevated intracellular Ca2+ levels in several models of
epileptogenesis (Raza et al., 2004; Raza et al., 2001; Sun et al., 2004). There are several
possible mechanisms that allow this extended elevated Ca2+ to lead to epileptogenesis.
Increased Ca2+ may alter GABA receptor recycling, altering neuronal excitability (Blair
et al., 2004). Elevated Ca2+ also alters gene transcription, protein expression and
turnover, neurogenesis, neuronal sprouting and many other physiological processes
(Morris et al., 1999). Indeed, pharmacologically blocking this extended elevation of Ca2+
inhibits epileptogenesis in in vitro models (Nagarkatti et al., 2010).
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Figure 1.
Flowchart of the events underlying neuronal cell death or epileptogenesis following
ischemia/stroke. Note that the increase in extracellular glutamate plays a central role in
the cascade of molecular events that lead to cell death or epileptogenesis. ATP –
adenosine triphosphate; Na+/K+-ATPase – energy dependent sodium potassium pump.
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Figure 1.
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E. Current models of epileptogenesis
Studying acquired epilepsy in the laboratory is a challenging task and the current
models do not necessarily reflect all the injury types that lead to epileptogenesis in
humans, so the need for more models of epileptogenesis is imperative. In addition,
studying acute seizure events in vivo and in vitro has been easier to accomplish than
actually producing epileptogenesis. Current methods of provoking acute seizure events in
vitro include the addition of agents such as 4-aminopyridine (Albus et al., 2008), or
pilocarpine (Poulsen et al., 2002), or by removal of magnesium from the extracellular
solution (Albus et al., 2008; Sombati and Delorenzo, 1995). In vivo models include the
use of pilocarpine (Raza et al., 2001), kainic acid (Cavalheiro et al., 1982),
organophosphates (Deshpande et al., 2010), and maximal electric shock (Wallace et al.,
2001). These insults produce acute seizures and have allowed for research into antiepileptic agents such as Levetiracetam (Angehagen et al., 2003) and carisbamate
(Deshpande et al., 2008). Models of epileptogenesis are more limited in the literature. In
vitro models include the low magnesium and glutamate injury models in hippocampal
neuronal culture (HNC) (Sombati and Delorenzo, 1995; Sun et al., 2001). The low
magnesium model utilizes the removal of magnesium from the extracellular solution for a
period of 3 hours. The removal of magnesium leads to excessive activation of the NMDA
receptor and subsequent electrical discharges by the cell, similar to the clinical correlate
of status epilepticus (Sombati and Delorenzo, 1995) Twenty-four hours after the
magnesium is returned to the media, the neurons display electrographic spontaneous
recurrent epileptiform discharges (SREDs). This model has provided valuable
information about the cellular processes that occur after a status epilepticus-like injury,
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resulting in epilepsy. Studies have shown that Ca2+ handling in these cells becomes
impaired and the intracellular Ca2+ concentrations remain elevated for the life of the
neuron (Pal et al., 2001). This model has also led to some insights about possible
pharmacological intervention to prevent epileptogenesis utilizing dantrolene (Nagarkatti
et al., 2010) or carisbamate (Deshpande et al., 2008). Hippocampal neuronal cultures
have also been utilized in the glutamate injury model of epileptogenesis (Sun et al.,
2001). Treating the cells with 20µm glutamate for 10 minutes causes a significant injury,
similar to what is observed during stroke (Sun et al., 2001). Similar to the low
magnesium model, the surviving cells have a continuously elevated intracellular Ca2+
concentration and develop SREDs (Sun et al., 2001; Sun et al., 2004).
In vivo models of epilepsy have generally focused on SE-like injuries by utilizing
various neuro-toxins. Pilocarpine is a muscarinic agonist commonly used to
experimentally induce SE. In the rat model of pilocarpine induced AE, rats are
administered a single dose of scopolamine (to block peripheral effects) before a single
dose of pilocarpine. Pilocarpine administration produces limbic seizures resulting in SE
and brain damage when administered to rats (Turski et al., 1983). Muscarinic cholinergic
excitation in the CNS is thought to occur as the result of blockade of K+ conductance,
mediated by voltage-dependent Ca2+ and Na+ conductances, resulting in prolonged
depolarizations and subsequent cellular damage (Turski et al., 1983). After latency period
of several weeks, rats begin to have spontaneous, recurrent seizures that persist for the
animal’s lifetime. This model has been thoroughly characterized and shows many
correlates to human temporal lobe epilepsy (Cavalheiro et al., 1991; Mello et al., 1993).
Similar to in vitro models, studies have shown a substantial increase in intracellular

12

neuronal Ca2+ during SE and following the injury. In fact, intracellular hippocampal Ca2+
levels remain elevated for the life of the animal (Raza et al., 2001). In contrast to in vitro
models, epileptogenesis following a stroke-like injury has been much more difficult to
produce. A cerebral artery occlusion model in perinatal rats has been successful in
producing acquired epilepsy (Kadam et al., 2010). This model is significant to studying
epilepsy associated with hypoxic-ischemic induced perinatal encephalopathies. However,
it is not an accurate model for the most common group affected by stroke AE; persons
over 65. In adult rats, Hartings et al. (Hartings et al., 2003) has shown that middle
cerebral artery occlusion does, in fact, produce non-convulsive seizures acutely following
the injury, but there are no animal models of stroke induced acquired epilepsy known in
the literature.
Stroke induced epilepsy is a major problem in modern neurology. Current models
in the laboratory can provide some insights, but they also have limitations. In vitro
models are ideal for studying individual cellular effects of an injury, but they are limited
by lost morphology when cells are cultured. Anatomic factors and the presence of
different cell types plays a role in the stroke penumbra, and these factors can not be
adequately studied in a hippocampal neuronal culture (HNC) model. In vivo models of
stroke have had limited success in producing AE, as current models have observed nonconvulsive seizures acutely, without monitoring the animals for long term acquired
epilepsy (Hartings et al., 2003). Perinatal models of ischemia have produced AE, but the
developing brain has many key differences from the adult brain in this model. In addition,
animal models are very costly and time consuming and may not be suitable for the first
step in testing new antiepileptic agents. These factors have led our laboratory to the
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development of an organotypic hippocampal slice culture model of acquired epilepsy.
Organotypic brain slice cultures maintain basal cellular and connective organization and
several fundamental in vivo-like characteristics that offer a feasible alternative located in
complexity between primary cell cultures and intact animals. Following an initial and
brief depression caused by explantation, many synaptic components are expressed at
steady levels in long-term hippocampal slice cultures, allowing detailed investigations of
mechanisms of brain synaptic function (Bahr et al., 1995).

F. Organotypic hippocampal slice cultures
The preparation of slice cultures was first developed in the 1970s (Crain, 1973) by
use of the static method in which a slice was incubated in a sealed Maximov chamber
with culture medium. This was followed by the roller-tube method in which slices are
adhered to a glass coverslip with a collagen or plasma clot and rotated in mediumcontaining tubes (Gahwiler, 1981). The properties of brain slices maintained in this
method have been described well (Gahwiler, 1988), however, most recent studies with
organotypic hippocampal slice cultures (OHSCs) utilize the interface method first
reported by Stoppini et al. (Stoppini et al., 1991). The interface method maintains slices
on a porous membrane at the air-medium interface. Cultures prepared with this method
are unique in that they are the first cultured tissues to exhibit long-term potentiation
(LTP) (Bahr, 1995). Extensive studies of OHSC development have revealed in vitro
similarities to normal in vivo development. The distinct laminar structure and the
morphology of different cell types is present at the time of culture and are well preserved
by long term culturing (Bahr et al., 1995). Glial markers develop gradually over the first
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2 weeks of culture, followed by a stable maintenance for at least 30-60 days, closely
matching the astrocyte proliferation and myelination profiles during rat brain
development in vivo (Bahr et al., 1994; Bahr et al., 1995; Bahr, 1995). In addition to
maintaining normal morphology and development, long-term hippocampal slice cultures
also reach a level of functional maturity. Studies have shown that long term cultures
possess the capacity for many synaptic plasticity events including paired-pulse
facilitation, post-tetanic potentiation, LTP, and inhibitory post-synaptic potentials (Bahr,
1995; Muller et al., 1993a; Stoppini et al., 1991; Vanderklish et al., 1995).
The maintenance of normal morphology and physiology has increased the
popularity of OHSCs in studying many neurological conditions. OHSC models have been
validated in many to investigate mechanisms and treatment strategies for
neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy,
and stroke (Cho et al., 2007; Noraberg et al., 2005; Sundstrom et al., 2005). Excitotoxic
injury has been induced in OHSCs by exposure to N-methyl-D-aspartate (NMDA), alphaamino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), kainic acid (KA), or
domoic acid. Interestingly, CA1 pyramidal cells are more susceptible to cell death upon
exposure to NMDA and AMPA (Kristensen et al., 2001; Noraberg et al., 2005), while
CA3 is more vulnerable to KA and domoic acid (Holopainen et al., 2004; Noraberg et al.,
2005). OHSCs have also been used extensively to study the stroke-like, energy failure
conditions in an oxygen-glucose deprivation injury (OGD). When exposed to OGD, CA1
pyramidal cells are the most susceptible, as in vivo, displaying NMDA glutamate receptor
mediated cell death (Bonde et al., 2005; Noraberg et al., 2005). OGD has been studied
extensively to examine various neuroprotective agents (Moroni et al., 2001; Pringle et al.,
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1996). However, the physiological consequences of excitotoxic or OGD injuries has not
been fully explored in OHSCs. An advantage of OHSCs is the ability to maintain and
study cultures long term after manipulation. This distinct advantage provides an ideal
system to study the long term physiological changes following a stroke-like injury.
Seizure activity in OHSCs has been studied using various methods. Using the
roller drum method of culture (Muller et al., 1993b) bicuculline and picrotoxin induce
epileptic activity and a reduction of dendritic spines. Other groups using bicuculline to
induce epileptiform activity in slice cultures grown in the interface method have
demonstrated increased gap junctional function and expression (Wang and Bausch,
2004). The application of kainic acid for 48 hours induced increased supragranular Timm
staining of mossy fiber and CA1 derived axonal sprouting onto dentate granule cells
(Routbort et al., 1999). They showed that this axonal sprouting contributed to
hyperexcitability in KA treated cultures. These studies support the use of OHSCs in the
development of models of acquired epilepsy.

G. History of Cannabis use to treat seizures
Ancient medicine has long known that Cannabis extract has pharmacological
properties useful for the treatment of many ailments. There is evidence from as early as
the BC era that Cannabis was used to treat pain (Lutz, 2004). Ancient eastern medicine
has also exploited Cannabis extract for the treatment of many other ailments, including
pain, headaches, insomnia, fever, and a variety of GI disorders. Perhaps one of the
earliest written testimonies of Cannabis use as a means to control seizures dates back to
1464. In a treatise on hashish written by the poet Ali ben Makki, it states that hashish was
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prescribed to the son of the Caliphate Councillor who was suffering from seizures. In
effect, “it cured him completely but he could not be without the drug ever after” (Lutz,
2004; Mechoulam, 1986). The use of hashish was widely illicit in medieval Arab society,
though it was widely used recreationally among the poor, therefore its use as an antiepileptic may have been influenced by Indian medical traditions, where Cannabis -based
medicines were often used to treat convulsions, along with many other neurological
disorders (Mechoulam, 1986).
Early medical studies of the therapeutic uses of Cannabis were not undertaken by
Europeans until the 1840s. The British scientist and physician O’Shaugnessy tested some
of the pharmacological uses of Cannabis by administering extracts of Cannabis resin to
patients with rheumatism, tetanus, rabies, infantile convulsions, cholera, and delirium
tremens. He reported that the convulsions and spasms associated with rabies and tetanus
were well controlled with high doses of the Cannabis extract. He also noted positive
results in cases of infantile convulsions (Mechoulam, 1986; Robson, 2001). After these
observations were published, the medicinal use of Cannabis expanded rapidly. By 1854,
Cannabis was in the United States Dispensatory and commonly used in many home
remedies (Robson, 2001). In 1890, a British neurologist named J.R. Reynolds, Queen
Victoria’s personal physician, reported on the role of Cannabis in the treatment of
epilepsy, stating that while Cannabis “was very useful for attacks of violent epileptic
convulsions, it was absolutely useless for attacks of petit mal epilepsy” (Mechoulam,
1986). However, the peak of the use of Cannabis as a home remedy had already passed
by that time due to variable potency, poor storage stability, unpredictable response to oral
administration, increasing availability of synthetic alternatives, and concerns about
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recreational use (Robson, 2001). Therefore, Reynolds’ report was largely ignored by the
medical community (Lutz, 2004). Cannabis was banned in the United States and other
countries in the early 20th century, hindering its use as a medical remedy.
Though the various Cannabis sativa preparations were the most widely used illicit
drugs in the world for centuries, little was known about the chemical composition until
the 1960s. The major active component of marijuana, ∆-9-tetrahydrocannabinol (THC),
was not isolated in a pure form until 1964 (Lutz, 2004; Mechoulam and Gaoni, 1965). In
addition, cannabidiol, another constituent of marijuana was also isolated. These
compounds were tested in various seizure models (discussed later), but their mechanisms
of action were not really understood until further studies elicited more information about
the brain’s endogenous cannabinoid system, known as the endocannabinoid system.

H. The endocannabinoid system
The endocannabinoid system consists of the two cannabinoid receptors (CB1 and
CB2), their endogenous ligands and associated enzymes. The cannabinoid CB1 and CB2
receptors are G-protein-coupled receptors (GPCRs) that belong to the rhodopsin GPCR
family (Reggio, 2006). The CB1 receptor is mainly found on neurons in the CNS, while
the CB2 receptor is found predominantly in immune tissues, though it is present at lower
levels in the CNS (Munro et al., 1993; Van Sickle et al., 2005). A major advance in
cannabinoid research came with the discovery and cloning of these unique receptor
proteins that mediated many of the behavioral and physiological effects of cannabinoids,
leading to the molecular characterization of the CB1 (Devane et al., 1988; Matsuda et al.,
1990) and CB2 (Munro et al., 1993) receptors. Further advancing the field was the
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discovery of several novel cannabinoid ligands and endogenous cannabinoid
(endocannabinoid) compounds, including the two major brain endocannabinoids, Narachidonyl ethanolamine (anandamide, AEA) (Munro et al., 1993) and 2arachidonylglycerol (2-AG) (Mechoulam et al., 1995), with regional differences in which
one or the other predominates in the brain (Alger, 2004). The CB1 receptor transduces
signals in response to AEA, 2-AG, and noladin ether, as well as ∆-9-THC (Reggio,
2006). It also transduces signals in response to synthetic compounds such as the nonclassical cannabinoid CP 55940 and the aminoalkylindoles, typified by WIN55212-2
(Reggio, 2006). Several CB1 antagonists have been reported, among them SR141716A,
AM630, LY320135, O-1184, and CP272871(Reggio, 2006). SR141716A has been shown
to exert is effects as a competitive CB1 antagonist, as well as an inverse agonist (Reggio,
2006).
The CB1 receptor is one of the most abundant neuromodulatory receptors in the
CNS, with levels up to 10 times that of any other GPCR (Herkenham et al., 1990; Sim et
al., 1996) and it is expressed at high levels in the hippocampus, cortex, cerebellum, and
basal ganglia (Herkenham et al., 1990; Herkenham et al., 1991; Tsou et al., 1998). The
endocannabinoid molecules and the endocannabinoid system regulate hippocampal
excitability (Ameri et al., 1999; Chemin et al., 2001; Steffens et al., 2003) and modulate
neuronal excitation and inhibition in animals and humans (Chen et al., 2003; Steffens et
al., 2004). In the hippocampus, it has been proposed that the endogenous cannabinoids,
AEA and 2-AG act as retrograde signaling molecules that mediate the suppression of
GABA release from presynaptic terminals following depolarization of a CA1 pyramidal
neuron. However, CB1 function has also been observed on glutamatergic terminals and
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transcripts encoding CB1 receptors were shown to be present in glutamatergic neurons of
the hippocampus and amygdala. Thus, the overall effect of CB1 receptor activation in the
hippocampus can be a reduction in both the inhibitory and excitatory transmission. In
addition, Hajos and Freund propose that in the hippocampus, CB1 receptors are
preferentially localized to GABAergic terminals and that another, non- CB1, non-CB2
cannabinoid receptor mediates the effects of CB1 receptor agonists on glutamatergic
release (Freund and Hajos, 2003; Hajos and Freund, 2002a; Hajos and Freund, 2002b;
Smith, 2005).
Discoveries in the last decade have been crucial to discovering the role of
endocannabinoid signaling as a regulator of synaptic communication. The molecular and
anatomical organization of the endocannabinoid system at most synapses also allows for
perturbations of the system to contribute to several neurological diseases. The CB1
receptor is the most abundant G-protein coupled receptor in the brain, with a density of
binding sites comparable to those of the two major neurotransmitters, glutamate and aminburtyric acid (GABA) (Devane et al., 1988; Herkenham et al., 1990; Katona and
Freund, 2008). The CB1 receptor is located on the presynaptic side of the synapse at
nearly all types of central nervous system synapses (Freund et al., 2003; Katona and
Freund, 2008). Presynaptic CB1 localization was first noted on GABAergic terminals,
though more recent evidence has shown CB1 receptors to be just as abundant on
glutamatergic projections (Katona and Freund, 2008). Glutamatergic projections with
CB1 receptors have been discovered on neocortical (Lafourcade et al., 2007),
hippocampal (Katona et al., 2006; Kawamura et al., 2006), hypothalamic (Wittmann et
al., 2007) and cerebellar (Kawamura et al., 2006) neurons. Other recent evidence also
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suggest CB1 activity exists in subcortical ascending pathways, such as cholinergic
(Degroot et al., 2006), noradrenergic (Oropeza et al., 2007), or serotonergic (Balazsa et
al., 2008) axons. Endcannabinoids may not be primarily involved in basal and tonic intraor inter-cellular communication, instead acting mainly as a on-demand intercellular
signaling system (Katona and Freund, 2008). This would suggest that only precisely
timed and positioned physiological stimuli evoke endocannabinoid biosynthesis and
release from a selected subdomain of the cell surface, allowing for a crucial role in
neuronal regulation, especially in disease states such as epilepsy (Katona and Freund,
2008).
Other intracellular effects in neurons after binding of agonists to CB1 receptors
are inhibition of adenylyl cyclase, leading to decreased levels of intracellular cAMP, and
stimulation of potassium channels (A-type and inwardly rectifying), leading to an
increased efflux of potassium (Lutz, 2004). Pharmacological and kinetic studies suggest
that CB1 activation inhibits presynaptic Ca2+ channels through direct G protein inhibition,
in a process termed depolarization induced suppression of inhibition (DSI) and it’s
analogous depolarization induced suppression of excitation (DSE). Cannabinoid-sensitive
inputs are unusual among CNS synapses in that they use N-, but not P/Q-type Ca2+
channels for neurotransmitter release, indicating that the endocannabinoids are highly
selective, rapid modulators of hippocampal inhibition. Collectively, CB1 receptor
agonists render neurons less excitable. Endocannabinoids inhibit neurotransmitter release
from nerve terminals that synapse on the endocannabinoid-generating cell. A major
mechanism of synaptic inhibition is the suppression of presynaptic voltage-gated calcium
channels, as shown by exogenous cannabinoids ability to block calcium currents (Alger,
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2004; Twitchell et al., 1997). During DSI and DSE, the suppression of synaptic
transmission is transient, lasting for only seconds. This indicates that DSI can facilitate
induction of long term potentiation (LTP). Since the strength of GABAergic inhibition
usually regulates the ability of excitatory synapses to induce LTP, DSI can induce weak
excitatory potentials that can induce LTP. Indeed, LTP does not occur if CB1 receptors
are blocked (Alger, 2004; Carlson et al., 2002). Hence, the endocannabinoid system may
play an important role in regulating synaptic plasticity.
The endocannabinoids AEA and 2-AG are thought to be synthesized on demand
as a result of neuronal excitation. The synthesis of anandamide is thought to take place in
two steps. First, N-arachidonyl phosphatidyl ethanolamine is formed from the precursor
phosphatidyl ethanolamine by the enzyme N-acyltransferase. Next, anandamide is
synthesized from N-arachidonoyl phosphatidyl ethanolamine by phospholipase D (Lutz,
2004). 2-AG is also thought to be synthesized in two steps from the precursor
phosphatidyl inositol, though two different pathways have been described. 1,2diacylglycerol and lysophosphatidyl inositol have been found to be intermediate
products. Two diacylglycerol lipase enzymes (DGL-alpha and DGL-beta) catalyze the
synthesis of 2-AG from 1,2-diacylglycerol (Lutz, 2004). Synthesis of 2-AG and
anandamide can be initiated by an increase in intracellular calcium concentration,
however a single action potential does not increase calcium concentration enough for
endocannabinoid production. Bursts of action potentials, such as those seen in seizures
and other excitatory events, can lead to endocannabinoid production (Alger, 2004).
The on-demand synthesis of endocannabinoids allows them to be used as a means
of local retrograde signaling. Because they can easily partition into and diffuse
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throughout cellular membranes, lipid messengers, such as AEA, are not easily contained
by physical boundaries, such as the vesicles that store cationic neurotransmitters. AEA
synthesis seems to be triggered by depolarization of the cell and consequent Ca2+ influx
(Reggio, 2006). Endocannabinoid synthesis may also be triggered by activation of group
I metabotropic glutamate receptors (mGluRs). Calcium does not seem to play a role in
this pathway, suggesting that depolarization and mGluR activation represent two separate
pathways to endocannabinoid synthesis, increasing the magnitude of DSI (Reggio, 2006).
With its ability to readily partition, the termination of AEA signaling poses another
problem. Termination cannot rely on uptake and compartmentalization as with classical
neurotransmitters. Instead, signaling termination must rely on chemical transformation. It
has been proposed that there is a specific transporter on both neurons and glia that
mediates endocannabinoid uptake, though others suggest that the process is by simple
diffusion (Reggio, 2006). Once taken into the cell, endocannabinoids are broken down by
membrane bound enzymes on the endoplasmic reticulum known as fatty acid amide
hydrolysis (FAAH) for the degradation of AEA (Di Marzo et al., 1998; Reggio, 2006)
and monoglyceride lipase (MAGL) for the degradation of 2-AG. FAAH is found
predominantly in the postsynaptic cell somata and dendrites, whereas MAGL is in
presynaptic nerve terminals (Alger, 2004) (Figure 2).
Recent developments of specific inhibitors for FAAH and MAGL have catapulted
endocannabinoid research in the past few years. The ability to specifically inhibit each
enzyme will allow for greater therapeutic opportunities in regulating specific
endocannabinoid channels (Petrosino and Di Marzo, 2010). The ability to modulate the
hydrolytic enzymes that control AEA and 2-AG levels potentially allows for more
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specific methods to modulate cannabinoid receptor activity without the unwanted
psychotropic effects that are typical of Cannabis preparations. A specific FAAH
inhibitor, such as Org-231295 has been suggested by preclinical studies as a possible
analgesic for inflammatory and neuropathic pain, and as a possible therapeutic agent for
depression and anxiety (Petrosino and Di Marzo, 2010). The specific MAGL inhibitors,
OMDM-169 (Bisogno et al., 2009) and JZL-184 (Long et al., 2009) have all been
suggested as possible analgesic agents in models of inflammatory or acute pain
(Petrosino and Di Marzo, 2010). These agents have yet to be examined in seizure models,
but the ability to specifically control endocannabinoid levels is enticing for future studies.
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Figure 2.
Schematic representation of the endocannabinoid system in pre- (top) and postsynaptic
(bottom) neurons. EMT – endocannabinoid membrane transporter, MAGL –
monoacylglyceride lipase, DAGL – DAG lipase, AEA – anandamide, NarPE – Narachidonyl phosphatidylethanolamine, NAT – N-acyltransferase. Taken from(Pacher et
al., 2006).
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I. Depolarization induced suppression of inhibition (DSI) and excitation (DSE)
In the early 1990’s, it was reported that brief depolarization of the CA1 pyramidal
cells in the hippocampus caused a reduction in the amplitude of the GABa ergic IPSCs
that lasted for several seconds (Alger, 2002; Pitler and Alger, 1992). This phenomenon
came to be known as depolarization induced suppression of inhibition and it has also
been recorded in Purkinje cells of the cerebellum (Alger, 2002; Llano et al., 1991;
Vincent et al., 1992) CA3 pyramidal cells (Morishita and Alger, 2000), dentate gyrus
granule cells (Isokawa and Alger, 2005) and neocortical pyramidal cells (Zilberter, 2000).
Various studies were done to isolate DSI as a retrograde signaling process, narrowing the
site of induction to the post-synaptic cell (Alger, 2002). However, the retrograde
messenger responsible for DSI remained unknown until strong evidence was reported
that the messenger was likely to be an endocannabinoid in the hippocampus (Alger, 2002;
Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2002). DSI in the hippocampus occurs
when the stimulation of the postsynaptic cell leads to the on demand production and
release of the endocannabinoid (Alger, 2002). The endocannabinoid then diffuses across
the synapse (or is carried) and binds with CB1 receptors on CCK-positive interneurons
that act at pre-synaptic cells. This in turn decreases release of GABA from the
interneurons, thereby suppressing the inhibition to the post-synaptic cell. It is important
to note that CB1 receptors are only found on CCK-positive interneurons (Hajos et al.,
2000; Katona et al., 1999) and therefore endocannabinoids are not capable of blocking all
GABA release surrounding a given neuron (Alger, 2002). In the hippocampus, DSI is
probably mediated by the endocannabioid 2-AG (Alger, 2002). Calcium is essential to the
expression of DSI, as it is initiated by voltage-dependent Ca2+ influx. Other research has
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shown that DSI disappears when the inward Ca2+ current disappears (Llano et al., 1991),
increases when [Ca2+ (out)] is increased (Lenz et al., 1998) and is prevented by the removal
of extracellular Ca2+ during the voltage step (Ohno-Shosaku et al., 1998). Other studies
have shown that the magnitude of DSI induced by a given voltage step is directly
dependent on the concentration of the intracellular Ca2+ chelator (Alger, 2002; Lenz et
al., 1998).
Depolarization induced suppression of excitation (DSE), the excitatory correlate
to DSI, was observed in several brain regions by employing a similar protocol as DSI,
however it could not be induced in the hippocampus following those protocols. OhnoShosaku et al (Ohno-Shosaku et al., 2002) discovered that DSE does in fact occur in the
hippocampus, but the voltage step of the post-synaptic cell must be approximately 10
times longer than the voltage step necessary to induce DSI. It was also discovered that
DSE was not as robust as DSI in the hippocampus, as EPSC levels were only reduced by
30% compared to a 50% reduction of IPSCs in DSI. Studies of DSE in the hippocampus
have recently been shown to be rather complicated, as DSE was expressed at Schaffer
collateral synapses, but not Perforant path synapses in the same CA1 neuron (Xu et al.,
2010), suggesting different functional expression of CB1 receptors at the two pathways.
The fact that DSE in the hippocampus requires a long voltage step indicates that DSE
may not be a physiologically relevant phenomena in normal cell signaling. However,
under hyperexcitably conditions such as an epileptic seizure, DSE may play a valuable
role in the control of neuronal excitability (Figure 3).
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Figure 3.
Schematic representation of the effects of cannabinoid signaling on excitatory and
inhibitory events. The traces below the figure represent excitatory and inhibitory postsynaptic potentials (EPSPs and IPSPs) before and after a depolarization of the postsynaptic cell. The decreased amplitude of the EPSP indicates that DSE has occurred
following 2-AG signaling. The decreased amplitude of the IPSP is representative of DSI.
Figure adapted from (Basavarajappa, 2007).
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Figure 3.
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J. ∆-9-THC’s anti-seizure effects
Though reports from the 1800s eluded to the anti-seizure properties of
cannabinoids, they were not explored in biomedical research until the 1940s. As early as
1947, Loewe and Goodman documented the anticonvulsant effect of Cannabis extracts in
the mouse maximal electroshock (MES) model (Mechoulam, 1986). After the isolation of
∆-9-THC in 1964 (Mechoulam and Gaoni, 1965), followed by several other
cannabinoids, including cannabinol, and cannabidiol (CBD), the use of cannabinoids as
anticonvulsants was further explored. Cannabidiol does not bind to cannabinoid
receptors, it is not psychotropic, and the molecular targets have not yet been identified
(Lutz, 2004), yet it has shown anticonvulsant effects in several studies. Wada’s group
was among the first to report the acute antiepileptic effects of ∆-9-THC in the rat model
of kindled seizures (Corcoran et al., 1973; Wada et al., 1973). Around the same time,
Karler’s group showed the anticonvulsant effect of ∆-9-THC and CBD, in the MES
model (Karler et al., 1973; Karler et al., 1974b; Karler et al., 1974d). In this model, an
electric current is applied via the cornea to produce tonic hind limb extension. The
suppression of the hind limb extension is considered as a measure of the anti-convulsive
activity of the tested compound (Lutz, 2004). Sofia et al. also used the MES model to
show that ∆-9-THC was more potent in increasing hind-limb extension latency and
preventing mortality than the other anticonvulsants phenytoin, phenobarbital, and
chlordiazepoxide (Sofia et al., 1976; Sofia and Barry, 1977). The acute antiseizure effects
of cannabinoids and their metabolites were also shown in several other models in various
species, including cats, baboons, gerbils, frogs, and chickens (Cox et al., 1975; Dwivedi
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and Harbison, 1975; Johnson et al., 1975; Karler et al., 1974c; Wada et al., 1975a; Wada
et al., 1975b).
Human studies of cannabinoids and epilepsy have been inconclusive. An early
clinical study from 1948 supported the anticonvulsant actions of two isomers of DMHP
(a synthetic analogue of THC), ∆6 ,10 -THC dimethylheptyl isomer, when administered
to institutionalized children with epilepsy (Mechoulam, 1986). These five children had
generalized seizures inadequately controlled with phenobarbital and phenytoin. Two of
the five became entirely seizure free with the synthetic ∆6 ,10 -THC dimethylheptyl
isomer treatment (Mechoulam, 1986). Several small clinical studies have examined the
effect of CBD on seizure frequency, since CBD does not have the psychoactive effects of
THC. These studies found either some reduction of frequency or no significant reduction
compared to placebo (Gordon and Devinsky, 2001). However, these studies used rather
low doses of CBD, suggesting that further studies are needed at higher doses. Another
epidemiologic study found that marijuana use appeared to be a protective factor against
first seizures in men (Gordon and Devinsky, 2001; Ng et al., 1990). Gordon and
Devinsky have also performed informal interviews of patients with active epilepsy who
have used marijuana intermittently or regularly and found that the majority (90.2%) did
not identify a relationship between their marijuana use and seizure frequency or severity
(Gordon and Devinsky, 2001). Another study at Harlem Hospital Center between 1981
and 1984 showed that heroin use is a risk factor and marijuana is a protective factor in
new-onset seizures (Zagnoni and Albano, 2002). Furthermore, a survey of the medical
use of Cannabis products in Germany showed that epilepsy (3.6%) was among the most
frequently mentioned indications (Zagnoni and Albano, 2002). Several case reports
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implicate the recreational use of marijuana in the regulation of seizure events. In one case
report, a patient suddenly developed ictal symptoms upon withdrawal from frequent
marijuana use (Ellison et al., 1990), leading to further questions of tolerance to
cannabinoids and the effects of withdrawal (to be discussed later). These inconclusive
results in human cases of epilepsy demonstrate the need to further explore the role of the
endocannabinoid system in various types of CNS insults, especially those known to lead
to epilepsy.

K. Endocannabinoid system: protector against excitotoxicity
Based on its nature as a retrograde messenger during excitatory events, it has been
proposed that the role of the endocannabinoid system is to protect the brain against
excitotoxicity (Mechoulam and Lichtman, 2003). The endocannabinoid system has been
studied in a variety of CNS disease models. Several pathological models support the
neuroprotective role of the on demand synthesis of endocannabinoids. Kainic acid (KA)
induced seizures show a 3-fold increase in anandamide, whereas models of traumatic
brain injury see 2.5 and 10-fold increases of anandamide and 2-AG respectively (Bahr et
al., 2006). Other pathologic models showing a significant increase in endocannabinoid
levels include models of Parkinson’s disease, multiple sclerosis, stress and schizophrenia
(Bahr et al., 2006). Bahr et al reviewed the literature of the effects of cannabinoid agents
on various models of CNS insult. They conclude that in models of excitotoxicity, reduced
neuronal damage is seen with application of ∆-9-THC, cannabidiol, anandamide,
methanandamide, WIN-55212-2, CP-55,940, HU-210, AM374 (FAAH inhibitor), and
AM404 (transport inhibitor). Reduced seizure activity is seen with treatment of UCM707
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(transport inhibitor) and cellular and functional protection occurs with a combination of
AM374 and AM404 (Bahr et al., 2006). Furthermore, in another mouse model, an
intrahippocampal injection of AMPA produced excitotoxicity. Modulation of both FAAH
and anandamide transport were shown to enhance endocannabinoid responses to the
injury, resulting in cellular protection as well as improved behavioral and memory
performance (Karanian et al., 2005; Karanian and Bahr, 2006). The role of the
endocannabinoid system in neuroprotection has been further supported by Marsicano and
colleagues. They used two mouse models: animals deficient in receptors and those
lacking CB1 receptors in the principal glutamatergic (excitatory) neurons of the forebrain
but not the GABAergic (inhibitory) interneurons of cortex. Both groups of mice exhibited
more severe seizures after treatment with kainic acid than did control animals. The CB1
receptor antagonist SR-141716A augmented seizures to a much greater extent in CB1
heterozygous mice than in wild-type mice but failed to influence the high seizure activity
of mice lacking CB1 receptors in principal neurons. They were able to show that
endogenous activation of CB1 receptors on principal neurons promote cell survival during
excitotoxicity while CB1 receptors on GABAergic cells exert a negligible function. This
shows that cell-type specificity and dynamic regulation appear to be fundamental features
of the highly efficient physiological protection provided by the endocannabinoid system
(Marsicano et al., 2003). It also supports the hypothesis that the antiseizure effects are
CB1 mediated, as shown in other models.
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L. Anti-seizure effects are CB1 mediated
In vitro and in vivo seizure models have been employed to explore the role of the
endocannabinoid system and CB1 receptors in particular. One in vitro model uses
primary hippocampal neuronal cultures. By removing magnesium from the culture
medium, the cells show high-frequency, continuous firing until the magnesium is
returned to the medium. This electrical behavior models the continuous excitatory period
similar to that seen in status epilepticus. After a period of epileptogenesis, the cells
continue to show spontaneous recurrent epileptiform discharges (SREDs) for the life of
the cultures (DeLorenzo et al., 1998). Cannabinoids have been shown to be effective anticonvulsants in this model and their effects have been shown to be CB1 mediated (Blair et
al., 2006; Deshpande et al., 2007d). They have also been shown to be more effective than
standard anticonvulsants during the period of high-frequency, status epilepticus-like
activity (Deshpande et al., 2007b). This is relevant to SE in humans, since 20% of cases
of SE are refractory to the initial treatment of two or more antiepileptic drugs, leading to
significant morbidity and mortality (Deshpande et al., 2007b). In addition, the model has
also shown that pharmacoresistance did not develop to the anticonvulsant effects of
cannabinoids, while pharmacoresistance did develop to benzodiazepines, which are
commonly used to treat status epilepticus (Deshpande et al., 2007a).
In vivo models have also implicated the anti-seizure effect of cannabinoids to be
CB1 mediated. Wallace et al demonstrated that anandamide and its analog O-1812 have
significant anticonvulsant effects in the MES model in mice and that these could be
blocked by SR141716A (Wallace et al., 2001; Wallace et al., 2002). Other studies from
the DeLorenzo laboratory have employed the pilocarpine model of temporal lobe
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epilepsy to demonstrate that the anticonvulsant effects of cannabinoids and
endocannabinoids are mediated through CB1 receptor activation. The pilocarpine model
represents a refractory epileptic condition, as the seizures are not easily treated by
conventional AEDs. This model has been employed by the DeLorenzo laboratory to
show that ∆-9-THC and WIN55212-2 completely blocked spontaneous seizure activity. It
was shown that it was, in fact CB1 mediated by administering the CB1 antagonist
SR141716A, which potentiated seizure duration and frequency, even to the level of SE
(Wallace et al., 2003).
In the kainic acid induced seizure model of temporal lobe epilepsy, hippocampal
glutamatergic neurons, where CB1 receptors are present at low but detectable levels, are
the central mediators of on-demand endocannabinoid-dependent protection against acute
excitotoxic seizures (Lutz, 2004). In this model, kainic acid (KA), an excitatory amino
acid found in seaweed, is injected systemically to induce strong activation of excitatory
pathways, inducing the hippocampus as the center of the seizures generated (Lutz, 2004).
Recent studies with this model have established that CB1 receptors expressed on
glutamatergic neurons are important mediators of the protective function in the KA
induced epileptiform seizures (Marsicano et al., 2003), that the endogenous cannabinoid
system is activated on demand when strong neuronal activation occurs, and that BDNF is
a central mediator of the long-term neuroprotective function (Khaspekov et al., 2004;
Lutz, 2004). In addition to studies implicating the endocannabinoid system as protective
in epileptogenesis, other studies have explored the role of cannabinoid compounds in
another common cause of seizures. CP 55940, WIN 55212-2, and anandamide were able
to significantly reduce lethality and seizure scores in cocaine-induced seizures (Hayase et
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al., 2001a; Hayase et al., 2001b). The authors suggest that dopamine receptors might also
play a role in this protective effect. Cocaine-induced lethality and seizures are closely
correlated with dopamine receptors and can be antagonized by dopamine antagonists
(Hayase et al., 2001a; Hayase et al., 2001b). Other studies have shown co-localization of
cannabinoid and dopamine receptors, suggesting a functional relationship between the
two receptor types in signaling protection. Another recent study by Naderi, et al showed a
synergistic anticonvulsant effect between the CB1 receptor agonist WIN55212-2 and the
classical anticonvulsant, diazepam, in the electroshock-induced seizure model in mice.
This suggests an interaction between the cannabinoidergic and GABAergic systems in
the modulation of seizures in mice (Naderi et al., 2008). The study also showed that
inhibition of FAAH by URB597 also produced significant antiepileptic effects in this
model (Naderi et al., 2008). By studying cannabinoid receptor function in various models
of seizures, it was also found that these receptors exhibit profound plasticity in their
distribution in models of long-term seizure activity.

M. CB1 receptor plasticity in disease states
CB1 receptor mRNA is present in the hippocampus of the rat brain as early as
gestational day 16. mRNA levels continue to rise until postnatal day 1, when levels then
decrease to their adult levels (Berrendero et al., 1999; Fernandez-Ruiz et al., 2000).
However, [35S]GTP S binding studies have revealed that the mRNA levels present at
early gestational ages do not signify functional receptors. CB1 receptor binding continues
to increase during development until it reaches adult levels (Berrendero et al., 1999;
Fernandez-Ruiz et al., 2000). Interestingly, hippocampal CB1 mRNA levels decrease in
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aged rats (2 years +) compared to young adults (3 months). However, there is no
difference in functional binding in the hippocampus of adult or aged rats (Berrendero et
al., 1998). The endocannabinoid system plays an important role in axonal guidance
during CNS development (Berghuis et al., 2007), which explains why mRNA levels may
be high during development.
Healthy adults maintain rather stable levels of CB1 receptors. However,
cannabinoid receptors have the ability to adapt in certain disease states, such as
Huntington’s disease, neuropathic pain, cerebral ischemia, and epilepsy. There is a loss of
CB1 receptor expression in the substantia nigra in Huntington’s disease (Glass et al.,
1993; Glass et al., 2000), with suggestions that it may be a protective and compensatory
response to the disease state (Glass et al., 2000). In Huntington’s disease, loss of CB1
receptor binding in key brain regions is detected early in human postmortem tissue (Glass
et al., 2000). A mouse transgenic model of Huntington’s disease (Lastres-Becker et al.,
2002) has shown similar decreases in CB1 mRNA in the basal ganglia. A detailed
analysis of the transgenic mouse model reveals that the CB1 receptor expression begins to
decrease before motor symptoms begin, suggesting a therapeutic time point in
intervention (Dowie et al., 2009). It has also been shown that CB1 receptor expression is
upregulated in a rat model of chronic neuropathic pain, indicating that the increased CB1
receptor expression may underlie the increased antinociceptive efficacy of cannabinoids
in chronic pain conditions (Siegling et al., 2001). In this rat model, CB1 receptors have
been shown to be upregulated in the contralateral thalamus after the unilateral axotomy of
the tibial branch of the sciatic nerve (Siegling et al., 2001). The authors suggest that this
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CB1 receptor upregulation contributes to the increased analgesic efficacy of cannabinoids
in chronic pain conditions (Siegling et al., 2001).
In a rat middle cerebral artery occlusion mode of stroke, Jin et al (Jin et al., 2000)
showed that CB1 receptor expression increased beginning by 2 hours and persisting for
72 hours or more after ischemia. Western blot and immunohistochemical studies showed
the CB1 receptor expression increased at the arterial boundary zone of the cortical mantle.
A more recent study used quantitative PCR to measure CB1 receptor mRNA content
following transient middle cerebral artery occlusion in mice and showed similar results:
the mRNA for the CB1 receptor in the brain ipsilateral to the occlusion was significantly
elevated at 1 hour, and maximally elevated 6 hours after the ischemia (Zhang et al.,
2008). In contrast, 5 hours of permanent middle cerebral artery occlusion had no effect on
CB1 receptor binding site density in male rats (Sommer et al., 2006). This suggests that
the increase in CB1 receptor following transient ischemia is a result of reperfusion rather
than ischemia.
CB1 receptors have also been demonstrated to show plasticity changes in epilepsy
in several studies. In the febrile seizure model of epilepsy, blockade of CB1 receptors
seems to play a protective role against CB1 reorganization. In the model, rats are exposed
to heat at postnatal day 10, increasing their core temperature to 41-42°C. When
monitored several weeks later, the rats show alterations in inhibitory neurotransmission in
the hippocampus, attributed to a potentiation of endocannabinoid signaling that was
caused by an increase in the number of presynaptic CB1 receptors on GABAergic
interneurons (Chen et al., 2003; Chen et al., 2007; Lutz, 2004). This model is clinically
relevant as there is a potential clinical association of prolonged, complex febrile seizures
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in infancy to temporal lobe epilepsy in adults. In this model, DSI was selectively
enhanced, but no changes of glutamatergic transmission were observed, implicating a
protective role of the endocannabinoid system (Chen et al., 2003; Chen et al., 2007; Lutz,
2004). They were also able to show that blocking the induction of this plasticity with CB1
receptor antagonists (SR141716A) abolished the long term effects of prolonged febrile
seizures in the developing brain (Chen et al., 2007). Notably, they also showed that
SR141716A had an acute proconvulsant effect, with beneficial chronic effects on seizure
thresholds (Chen et al., 2007). The DeLorenzo laboratory has also shown that there is a
long-term plasticity change in the expression of the CB1 receptor with the induction of
epilepsy in the pilocarpine model of acquired epilepsy in the rat. They demonstrated that
status epilepticus causes a unique “redistribution” of hippocampal CB1 receptors,
consisting of specific decreases of CB1 expression and corresponding functional changes,
while other areas showed increases in expression and function (Falenski et al., 2007).
These results demonstrated that status epilepticus causes a unique and selective
reorganization of the CB1 receptor system that persists as a permanent hippocampal
neuronal plasticity change associated with the development of acquired epilepsy
(Falenski et al., 2007). A more recent study has shown that these changes occur in a timedependent manner. One week following SE injury, there is a prominent loss of CB1
receptor immunoreactivity throughout the hippocampus. When rats began displaying
spontaneous seizures at 1 month post-SE, the CB1 receptor distribution was characteristic
of that observed in long term epileptic rats (Falenski et al., 2009). Specifically, the study
noted decreases in CB1 receptor immunoreactivity in the stratum pyramidale neuropil and
dentate gyrus inner molecular layer, and increases in the strata oriens and radiatum of
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CA1-3 (Falenski et al., 2009). These studies suggest that the dysregulation of CB1
receptor expression has a temporal correlation with the emergence of recurrent seizures.
The localization of the CB1 receptor changes indicates that the upregulation of CB1
receptors is at the glutamatergic terminals, suggesting that the increase in CB1 receptors
may act as a compensatory mechanism to control epileptic seizures and prevent SE. In
addition, a downregulation of CB1 receptors at the GABAergic synapses would allow for
greater inhibition during seizure events.
Other studies of reorganization of CB1 expression have been demonstrated in
human tissue. A recent study of by Ludanyi et al. used hippocampal tissue from epileptic
and seizure free humans (Ludanyi et al., 2008). The study used expression profiling and
quantitative electron microscopic analysis to show a major downregulation of CB1
receptors in the hippocampal formation of patients with intractable temporal lobe
epilepsy. This downregulation was mostly seen on the glutamatergic synapses of the
hippocampus, with a portion of the CB1 downregulation occurring in mossy cells. The net
effect of downregulation of CB1 at these excitatory synapses is that excitatory synapses
innervating granule cell dendrites will remain without negative feedback control in the
epileptic dentate gyrus (Ludanyi et al., 2008). They also found no significant changes in
the number of CB1-positive GABAergic interneurons, confirming findings from earlier
animal studies. These results suggest that the patients with intractable epilepsy may not
have had the compensatory upregulation of CB1 receptors at glutamatergic synapses to
aid in the control of seizures that is observed in the rat pilocarpine model.
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N. Cannabinoid pro-convulsant effects and tolerance
The large number of studies implicating cannabinoid compounds as
anticonvulsants are in direct conflict with several studies and reports that implicate
cannabinoids as proconvulsant agents. In the early anticonvulsant studies of the 1970s,
administration of ∆-9-THC produced convulsions in a population of rabbits (Consroe et
al., 1977) and epileptic beagle dogs (Mechoulam, 1986). However, convulsions do not
occur in these animals with CBD and other nonpsychoactive cannabinoids, even with
higher doses. Mechoulam reviewed literature in which ∆-9-THC, given by intravenous,
oral, and inhalation routes caused convulsions in non-seizure susceptible animals, though
he notes that these convulsions occurred only with lethal or near-lethal doses given
acutely or high doses given repeatedly for months (Mechoulam, 1986). In some
experimental models of seizure, namely the iron- or cobalt-induced epileptic rat, the
aluminum-induced epileptic cat, and the limbic-kindled epileptic rat, low doses of ∆-9THC and some THC compounds can elicit convulsions, while similar or higher doses of
CBD do not (Chiu et al., 1979; Mechoulam, 1986). How can cannabinoids act in opposite
fashion in different models? This paradox can be reconciled in part by considering the
dual role that endocannabinoids are known to play in the brain. Endocannabinoids are
able to elicit inhibitory effects by blocking glutamate release or excitatory effects by
blocking GABA release, depending on which neural circuits are activated (Mechoulam
and Lichtman, 2003). FAAH knockout mice represent one model that shows a
proconvulsant effect. FAAH is responsible for breaking down anandamide in the brain,
therefore FAAH knockouts show an increased endogenous level of anandamide. These
mice show a lower seizure threshold and FAAH regulated proconvulsant and neurotoxic
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activity (Clement et al., 2003). This effect is reasonable due to the fact that the activation
of the endogenous cannabinoid system was not cell-type specific as it is active in both
GABAergic and glutamatergic neurons and not in an appropriate time-course, as CB1
receptors were activated for a long period of time. Nakatsuka et al also demonstrated that
cannabinoids can potentiate epileptiform activity where CB1 receptors are localized to
GABAergic terminals in patch clamp experiments using granule cells of the human
dentate gyrus (Nakatsuka et al., 2003). They showed that the activation of CB1 receptors
could suppress inhibitory synaptic activity. Bath application of WIN 55212-2 suppressed
the frequency of spontaneous inhibitory post-synaptic currents and AM251 completely
blocked these effects, suggesting that they were mediated by CB1 receptors (Smith,
2005).
In considering cannabinoids as a potential treatment of seizures, the issue of drug
tolerance must also be considered. In some of Karler’s early studies of cannabinoids in
the MES model, they noted the development of tolerance to the anticonvulsant effects of
cannabinoids (Colasanti et al., 1982; Karler et al., 1974a; Karler and Turkanis, 1980).
Complete tolerance of ∆-9-THC to MES anticonvulsant effects has been reported in as
early as 3-4 days. Cross-tolerance of ∆-9-THC tolerant animals to phenytoin and
phenobarbital also occurred (Karler et al., 1974a). It was also shown that withdrawal after
repeated high-dose administration might increase seizure susceptibility in some epileptic
animals (Karler and Turkanis, 1980). Chronically administered cannabinoids produce
tolerance to their acute behavioral effects, in which the potency or efficacy of the drug
changes such that the physiological and/or psychological consequences of the same drug
dose are significantly diminished with repeated use (Martin et al., 2004). However, this
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tolerance to in vivo cannabinoid effects does not appear to result from alterations in
cannabinoid pharmacokinetics (Martin, 1986; Martin, 2005). Continued administration of
cannabinoids can also lead to dependence in humans, as well as in increased levels of
dopamine in the nucleus accumbens of animals (Smith, 2005). The issues of tolerance
and dependence have not been thoroughly explored in regards to the use of cannabinoids
as anti-epileptics, but they deserve further attention as the prevalence of Cannabis use
among American adults is about 4%, with 30% of users reaching levels of dependence
(Compton et al., 2004). Recreational marijuana users with epilepsy may represent a
significant patient population. Furthermore, there may be a statistically unknown number
of patients with epilepsy who choose to use cannabinoids as a means of “self-medication”
for their condition.

O. Future directions, potential therapies
The exploitation of the brain’s endogenous system of controlling excess
hyperexcitability is logically a potential target for epilepsy therapeutics. Because of its
ubiquitous nature, it is important that future studies of cannabinoids in the treatment of
epilepsy must be focused on the brain regions and cells at the focal point of the seizures.
The potential problem in delivering a cannabinoid drug to treat epilepsy is the inability to
control its actions at different cannabinoid receptors regulating the release of different
neurotransmitters. Animal studies, as well as information from human studies have
shown conflicting results as to cannabinoids pro- or anti-convulsant effects. The effect
may be mediated by the type and focal point of the seizures, as well as origin, whether it
be genetic in nature or precipitated by a neurological insult. The location of CB1
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receptors at either glutamatergic or GABAergic synapses helps to explain the dual actions
of cannabinoids in regards to anti-seizure activity. As there are many types and causes of
epilepsy, it is clear that the endocannabinoid system may not be an effective target for all
forms of epilepsy. Lutz proposes that a potential therapeutic endocannabinoid target lies
in the uptake inhibitors (Lutz and Monory, 2008). By inhibiting anandamide uptake, CB1
receptors would remain activated in the synapses that are producing the
endocannabinoids on demand. This mechanism would more specifically target the
glutamatergic synapses, while having less of an effect on the pro-convulsant GABAergic
synapses. Several uptake inhibitors have been characterized, AM404, UCM707, OMDM1, and OMDM-2. He reasons that targeting uptake may be more beneficial than
prolonged application of CB1 receptor agonists, since prolonged application may actually
lead to a down-regulation in CB1 receptor level. Interestingly, these inhibitors evoke
much less or even no psychotropic effects as compared to CB1 receptor agonists (Lutz,
2004). Further research needs to be done with these compounds, as current studies have
produced mixed results (Marsicano et al., 2003; Naderi et al., 2008). Enhancing
endocannabinoid tone is perhaps a safer approach than using exogenous
endocannabinoids. Recent studies suggest that the unique pharmacology of
endocannabinoids reduces the cellular changes underlying tolerance and allows for a
greater control over CB1 responsiveness (Bahr et al., 2006). Endogenously released
cannabinoids can lead to markedly different outcomes in synaptic physiology compared
to exogenously applied CB1 agonists. In addition, Lutz and Monory have recently
proposed targeting CB1 receptors to prevent the development of epilepsy following
febrile seizures in infants (Lutz and Monory, 2008). They reason that acute blockade of
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CB1 on GABAergic terminals during neuronal excitability of febrile seizures leads to a
decrease of hyperexcitability in these cells, preventing the upregulation of CB1 that leads
to a lowered seizure threshold. However, they note that acutely blocking CB1 on
glutamatergic terminals is pro-convulsant during a critical period of initial neuronal
insult. Still, the idea of manipulating the endocannabinoid system during or shortly after
the precipitating event of epileptogenesis is intriguing as a possible mechanism to prevent
the plasticity changes seen in CB1 receptor organization in epileptic animals and humans.
Further research is needed to examine the potential of targeting the endocannabinoid
system to prevent epileptogenesis and to control seizures in those suffering from the
debilitating disease. As noted by Robert Christison in 1848 as he investigated the many
beneficial effects of Cannabis, it “is a remedy which deserves a more extensive
inquiry…” (Alger, 2004; Piomelli, 2004).

P. Summary and rationale
Cerebral ischemia is a catastrophic event with significant morbidity and mortality.
It is the leading cause of acquired epilepsy in persons 35 and older (Forsgren et al.,
1996), yet little is known about the underlying basic mechanisms leading to stroke
induced epilepsy. Compared to the general population, patients who have suffered a
cerebral infarct have a 17-fold greater risk of developing recurrent seizures (Warlow et
al., 2003). In addition, 30% of patients with epilepsy do not obtain satisfactory control of
their seizures with the medical and pharmacological interventions currently available
(Morimoto et al., 2004), underscoring the need for greater research about stroke induced
epilepsy.
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Models of stroke induced epilepsy are difficult to come by. An in vitro model
utilizing hippocampal neuronal cultures has successfully modeled many aspects of the
ischemic penumbra (Sun et al., 2001) and has developed electrographic seizures
following the injury. In vivo models of stroke induced epilepsy have been more difficult
to study. Acute non-convulsive seizures follow middle cerebral artery occlusion in adult
rats (Hartings et al., 2003) and perinatal models of ischemia have been shown to produce
acquired epilepsy (Kadam et al., 2010). However, there haven’t been any good models
for stroke acquired epilepsy in vivo, therefore a more intact in vitro system is appealing to
study the molecular changes following stroke.
Organotypic hippocampal slice cultures have been utilized for years in various
studies of stroke and seizures. They have a distinct advantage over HNC in vitro models
in that they maintain normal cellular morphology and architecture and continue to
develop in culture (Bahr, 1995), while allowing for easy manipulation. They are between
HNC and in vivo models in terms of complexity and can assist in answering many basic
physiological and anatomical questions. OHSCs have been studied extensively in
oxygen-glucose deprivation and glutamate injuries to mimic the effects of ischemia. Most
studies have focused on manipulating the system to prevent cell death, while few have
looked at the long term physiological outcomes. In addition, few studies have utilized
OHSCs to produce spontaneous recurrent seizures as a model of epilepsy (Bausch et al.,
2006; Routbort et al., 1999). With this in mind, it seems that OHSCs would be an ideal
substrate to study the physiological consequences of a stroke-like injury.
There is a plethora of experimental data to suggest that modulation of the
endocannabinoid system plays a role in epilepsy. Our laboratory has extensively studied
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the endocannabinoid system in the rat pilocarpine model of epilepsy. Studies have found
that there is a unique, functional redistribution of CB1 receptors in the hippocampus
during the development of epilepsy (Falenski et al., 2007; Wallace et al., 2003), with an
overall increase in CB1 receptor expression. Evidence also exists that the
endocannabinoid system undergoes upregulation in cerebral ischemia (Hillard, 2008). A
model of stroke induced acquired epilepsy would provide an ideal system for studying
the endocannabinoid system following stroke-like injury. Studies have shown the OHSCs
express CB1 receptors similarly to in vivo tissue (Boscia et al., 2008), indicating that
OHSCs are an appropriate system to study CB1 receptor changes in vitro. In addition, the
ability to maintain OHSCs for long periods of time after a manipulation is an advantage
to using such an in vitro system to study long-term changes after an injury. The ease of
manipulation also makes an OHSC model ideal for performing electrophysiological and
immunohistochemical studies. Based on strong evidence from in vitro and in vivo studies,
we propose the development of an OHSC model of stroke-induced acquired epilepsy to
further study the anatomical and physiological changes associated with the
endocannabinoid system.

Q. Central hypothesis
We hypothesize that status epilepticus and stroke like injuries will cause increased
neuronal excitability in organotypic hippocampal slice cultures, rendering a model of
acquired epilepsy. In addition, we hypothesize that the endocannabinoid system plays a
modulatory role in stroke-induced acquired epilepsy in our OHSC model. Addressing the
following experimental questions in this dissertation will rigorously test our hypotheses.
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1. Does a status epilepticus like injury induce spontaneous
recurrent epileptiform discharges in our organotypic
hippocampal slice cultures?
2. Does a stroke-like injury induce spontaneous recurrent
epileptiform discharges in adult-equivalent organotypic
hippocampal slice cultures?
3. Are CB1 receptors upregulated in OHSCs that display seizure
activity? What is the distribution of the CB1 receptors?
4. Is there a functional difference in CB1 receptor activity
following a stroke-like injury?
An organotypic hippocampal slice culture protocol has been established in our
laboratory specifically to address the questions raised in this dissertation. Experimental
results from this dissertation establish the use of OHSCs as a model of acquired epilepsy
following a status-epilepticus like injury or a stroke-like injury. Electrophysiological and
cell death assays were employed to study the injuries and assess the physiological
consequences to neuronal hyperexcitability. Immunohistochemical and western blot
techniques were utilized to examine the CB1 receptor distribution in OHSCs following
stroke-like injury. Electrophysiological analysis of DSI and DSE following stroke-like
injury indicate that the CB1 receptor distribution changes following glutamate injury is
functional and possibly plays a role in controlling neuronal excitability in an epileptic
state.
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CHAPTER 1: 4-AMINOPYRIDINE TREATMENT CAUSES RECURRENT,
SPONTANEOUS SEIZURES IN AN ORGANOTYPIC HIPPOCAMPAL SLICE
CULTURE MODEL OF ACQUIRED EPILEPSY

A. Introduction
Epilepsy is a significant problem in neurology affecting approximately 2.7 million
people in the United States and costing at about $15.5 billion a year in medical costs and
lost or reduced earnings and productivity (Kobau et al., 2005). Epilepsy is a debilitating
disease with a significant impact on quality of life. Furthermore, approximately 30% of
patients living with epilepsy have seizures that are not adequately controlled via medical
intervention. Among cases of epilepsy, epidemiological studies have revealed that the
cause of epilepsy was unknown in 68% of the cases and preceded by a brain insult in
31% of the cases (Shneker and Fountain, 2003). The brain insults that are known to lead
to acquired epilepsy (AE) include stroke, CNS infection, traumatic brain injury, and
status epilepticus (DeLorenzo, 2006). Acquired epilepsy is a serious clinical problem,
but it has been challenging to develop good experimental models in the laboratory to
carefully study the neurological changes that occur during the development of epilepsy
(epileptogenesis) after a brain insult. Because of the severity of this problem worldwide,
it is important to develop new models of acquired epilepsy to allow for screening of
novel anti-epileptic drugs that may provide seizure relief for patients with refractory
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seizures while elucidating possible molecular targets to prevent epileptogenesis following
brain insult.
Organotypic hippocampal slice cultures (OHSCs) are a useful tool in epilepsy
research as they are easy to manipulate, can be maintained in culture for long periods of
time and are more cost effective than animal models while still maintaining normal
anatomical morphology (Stoppini et al., 1991; Sundstrom et al., 2005; Zimmer and
Gahwiler, 1984). OHSCs have been used for years to study acute epileptiform activity.
To induce this activity, epilepsy researchers have used convulsant drugs such as
pilocarpine, kainic acid, and 4-aminopyridine (Bausch and McNamara, 2000; Gutiérrez et
al., 1999; Wahab et al., 2010a; Wahab et al., 2010b). In addition, serum deprivation and
perfusion with a media containing no magnesium has also been shown to produce acute
epileptiform activity in OHSCs (Albus et al., 2008). However, few studies have used
OHSCs to produce a model of acquired epilepsy wherein spontaneous epileptiform
events occur following an injury. Spontaneous seizure events are known to occur in a
small number of OHSCs after long term in culture (Bausch and McNamara, 2000;
McBain et al., 1989; Routbort et al., 1999), but few studies have shown an injurious
manipulation leading to an increase in seizure activity. Bausch et al (Bausch et al., 2006)
showed an increase in seizure activity in OHSCs after long-term treatment with TTX and
subsequent removal of the sodium channel blocker. Activity deprivation causing AE led
to interesting insights of morphological changes in the seizing OHSC, but is not
representative of a brain injury leading to AE. Similarly, the same group employed kainic
acid as a method of injuring OHSCs. In this model, they found no significant difference
in spontaneous seizure activity between injured slices and controls after 40 days in vitro,
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however they were able to show increased hyperexcitability in granule cells of injured
OHSCs (Bausch and McNamara, 2004).
Because of their usefulness in epilepsy research, other methods of injury are
worth exploring for their potential to cause AE in OHSCs. The classic convulsant 4aminopyridine, (4-AP) has been used in animal models of SE wherein i.p. injection
causes tonic-clonic seizure activity in mice (Medina-Ceja et al., 2008). In addition, 4-AP
has recently been shown to acutely produce seizures in OHSCs that are refractory to most
standard anti-epileptic drugs (AEDs) (Albus et al., 2008). 4-AP interferes with several
types of K+ channels that include the D type and A type K+ currents and a subportion of
delayed rectifier currents (Wahab et al., 2010a). Blocking K+ channels interferes with the
cell’s ability to repolarize, prolonging action potentials and increasing the amount of
neurotransmitter released. Since exposure to 4-AP acutely caused drug refractory seizures
in OHSCs, we sought to explore the long term effects of using 4-AP to produce a SE-like
injury.

B. Methods

Organotypic hippocampal slice culture preparation
Slice cultures were prepared using the method of Stoppini et al. (Stoppini et al.,
1991), as previously reported by (Schanuel et al., 2008). All animal use protocols are in
strict accordance with the National Institute of Health guidelines and are approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Postnatal day 8 (P8) Sprague-Dawley rat pups (Harlan, Frederick, MD, USA) were
deeply anesthetized with isoflurane and decapitated. The brains were removed, and
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hippocampi were dissected out and cut into 350-µm transverse sections using a McIlwain
tissue chopper (Brinkmann Instruments, Canada) and placed into Hank’s balanced salt
solution [HBSS – Gibco BRL (Invitrogen, Carlsbad, CA, USA)] supplemented with 0.5%
sucrose and 1% penicillin-streptomycin. The middle four to six slices of each
hippocampus, including part of the entorhinal cortex, were placed onto tissue culture
membrane inserts (Millipore, Bedford, MA) in a 6-well tissue culture dish containing
medium consisting of 50% minimum essential medium, 25% horse serum and 25%
HBSS, 1% penicillin-streptomycin [all from Gibco BRL (Invitrogen, Carlsbad, CA)] and
supplemented with 36 mM glucose, and 25 mM HEPES (Sigma, St. Louis, MO, USA)
(pH 7.2). Cultures were maintained at 37°C under room air +5% CO2. After 1 day in
culture, culture medium was replaced with fresh medium containing no antibiotics.
Culture medium was replaced two times a week thereafter.

Field potential recording with acute 4-AP application
To observe the acute effects of 4-AP, several OHSCs were recorded at DIV 10. A
portion of the tissue culture insert membrane containing a single cultured slice was placed
into an interface slice recording chamber (Harvard Apparatus, Holliston MA) mounted on
a vibration table and viewed through a dissecting microscope (Diagnostic Instruments,
Sterling Heights, MI). Slice cultures were perfused (2–3 ml/min, gravity feed system)
with artificial cerebrospinal fluid a minimal essential medium (MEM) (containing in
addition to amino acids and vitamins (in mM): NaCl 105, KCl 3, NaH2PO4 1.25, MgSO4
1.8, CaCl2 1.6, glucose 10, NaHCO3 26.3 mM, pH 7.40, osmolality 265 mosm)
equilibrated with 95% O2-5% CO2. Recording pipettes were pulled on a Flaming Brown
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P-80 PC Micropipette puller (Sutter Instrument Co, Novato, CA) filled with 3.5 M NaCl
for extracellular recordings to achieve a resistance of 2-4 M . Data were collected with
an AxoClamp 2B (Molecular Devices, Union City, CA) recording amplifier and FLA-01
Bessel filter unit (Cygnus Technologies, Inc, Delaware Water Gap, PA) and pCLAMP
9.0 software (Molecular Devices). After a 15 minute equilibration period in aCSF,
200µM 4-AP was added to the perfusant and field potentials were recorded at 34°C in the
CA3 pyramidal cell layer. OHSCs were perfused with the drug for 45 minutes before
wash-out with normal MEM.

4-AP injury
After 10 days in vitro (DIV10), slice culture media was removed and replaced by
media containing 200µM 4-AP for 24 hours. Drug containing media was then removed
and slice cultures were washed with HBSS at 37°C two times before returning to normal
media. Control slices received normal media (without glutamate) during the 24 hour time
period, followed by washing with HBSS twice before returning to normal media.

Neuronal death assay
Neuronal death was assessed 24 hours, 5 days and 14 days after 4-AP treatment
by measuring uptake of the fluorescent dye Propidium Iodide (PI), using established
procedures (Lipski et al., 2007; Pomper et al., 2001). Greater PI uptake indicates greater
cell death. Cultures were exposed to 2 µM PI for 4 hours in normal culture media before
injury to assess pre-injury cell death. PI concentration was maintained in the culture
during injury and for the following 14 days. Before recording dye uptake under
fluorescent light, a phase contrast picture of each slice was taken so that orientation in the
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field could be maintained in subsequent recordings. Dye uptake was recorded on an
Olympus CK40 inverted microscope coupled to a QColor 3 camera and QCapture
software (Olympus, Center Valley, PA). All optical parameters (illumination aperture,
neutral density filters etc.) as well as the camera exposure time and electronic gain, were
standardized and kept constant. The fluorescent signal was measured densitometrically
using the Image-J software (NIH). The perimeter of each slice was outlined (identified in
phase contrast image) and the mean pixel value (0–255) was recorded and converted to a
scale of 0-100. All measurements were made after subtracting background fluorescence
(region positioned immediately outside the culture). Cell death was expressed as a
percent of mean pixel value of age matched controls.

Field potential recording for delayed seizures
At DIV 25-26, a portion of the tissue culture insert membrane containing a single
cultured slice was placed into an interface slice recording chamber. Field potential
recording parameters were the same as reported for acute 4-AP application. After a 15
minute equilibration period in MEM, field potentials were recorded at 34°C in the CA3
pyramidal cell layer. If spontaneous activity was not observed in the first few minutes,
slices were tested for viability by hilar stimulation (0.3-ms square pulse, 0.03 Hz, 50–150
µA) using a bipolar concentric electrode (FHC, Inc., Bowdoin, ME) and a stimulator
(World Precision Instruments, Sarasota, FL). OHSCs were first tested for viability by
stimulating in the dentate gyrus while recording in the CA3 cell layer (Figure 4). Slices
were considered acceptable if stimulation elicited an action potential spike that
immediately followed the stimulus artifact with a response threshold 150 µA (Bausch
and McNamara, 2000; Bausch et al., 2006). Neither the amplitude of the spike nor the
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shape of the waveform was used as criterion for acceptable recordings. Each slice culture
was recorded at 2 minute intervals (2 minutes on, 2 minutes off) over a 20 minute time
period, for a total of 10 minutes of recorded activity. Recordings were scored for seizure
events by two separate individuals who were blinded to the treatment group.

Data analyses
Data are expressed as mean ± SEM. To determine significance between treatment
groups for neuronal death assays, Student’s t-tests were used. For extracellular
recordings, z- test was used. In each experiment, n refers to the number of OHSCs. For
neuronal death assays, glutamate treated slices were normalized to control slices
harvested from the same animal. All experiments were performed over the period of
several weeks to months so that the results were representative of multiple cultures. A Pvalue < 0.05 was considered significant. Statistical analysis was performed using
SigmaStat 2.0 software (Systat Software, San Jose, CA, USA) and graphs were drawn
using Microsoft Excel for Mac software (Microsoft corporation).
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Figure 4. A. Phase contrast photo (4X) of an OHSC at DIV 21 - Cell layers of the
dentate gyrus (DG), CA3 and CA1 are clearly visible. B. Field potential recording of
OHSC- To test viability of OHSCs during field potential recording, the stimulating
electrode is placed in the DG while the recording electrode is placed over the CA3 cell
region. The trace shows an example of an evoked field potential recording from a viable
OHSC. The stimulus artifact is followed by the field potential.
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Figure 4
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C. Results
4-AP acutely causes seizure activity
At DIV10, perfusing OHSCs with MEM containing 200 M 4-AP caused high
frequency electrical discharges as observed with field potential recording. Recording of
the CA3 cell area demonstrated low frequency bursting, generally beginning within the
first 10 minutes of 4-AP perfusion (Figure 5). This bursting evolved into high frequency
tonic-clonic like discharges (Figure 6) that continued in the presence of 4-AP. These
events were comparable to in vivo SE, as one event followed another or evolved into a
state of continuous activity. These high-frequency events lasted up to an hour in these
experiments and have been reported to last up to 120 minutes (Albus et al., 2008) in the
literature.

4-AP exposure causes cell death
Addition of 200µM 4-AP to the slice culture media for a 24 hour period
significantly increased PI uptake just prior to removal of the drug. Propidium iodide
uptake was measured again at 5 and 14 days following the injury. When expressing PI
uptake as a percent of control, 4-AP treated OHSCs showed a 171±18.6% (n=24)
increase in PI uptake (control = 100 ±18.8%, n=12, P=0.023) at the end of the injury
period. However, the difference in PI uptake was not significantly different between the
two groups at 5 days [treated =121.8 ± 6.5% (n=17), control=100±9.8 (n=8), P=0.078] or
14 days [treated = 120.1 ± 7.0% (n=17), control = 100± 8.23 (n=8), P=0.106] following
4-AP treatment. This indicates that the majority of the cell death from the excitotoxic
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injury occurs acutely, which is similar to what is observed in other in vitro models of SE
induced acquired epilepsy (Deshpande et al., 2007c) (Figures 7 and 8).

4-AP induces long-term changes in OHSC excitability.
To investigate changes in OHSC excitability, we obtained field potential
recordings from the CA3 region of OHSCs 14 days after 4-AP injury to allow for a
period of epileptogenesis. Slices were recorded in normal physiological media without
the addition of pharmacological agents or the use of stimulation to induce seizure
activity. Representative field potential recordings of control and 4-AP treated OHSCs are
shown in Figure 9. Seizure events were defined as the abrupt onset of a high amplitude
burst of rhythmic activity superimposed on a field depolarization shift that lasted 3 s,
during which the waveforms evolved over time and terminated abruptly (Bausch et al.,
2006; Routbort et al., 1999). Field potential recordings showed seizure events in 62% of
4-AP treated OHSCs (n= 37) compared to 30% of control slices (n= 20, P=0.006, z-test)
(Figure 10). While some control and injured slices displayed individual action potentials
and brief depolarizing shifts, these slices were not considered to have seizure events
unless the burst of activity occurred for greater than 3 seconds. These electrographic
seizures displayed both ictal and interictal activity, similar to what is observed in in vitro
and in vivo seizure models, as well as in EEG recordings of human epilepsy.
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Figure 5 – 4-AP perfusion, 5 minutes
Field potential recording of a DIV 10 OHSC after 5 minutes of 200µM 4-AP perfusion.
Short bursts begin to appear within the first 10 minutes of perfusion with 4-AP. High pass
filtered offline at 10Hz.
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Figure 5
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Figure 6 - 4-AP perfusion, 25 minutes.
Field potential recording of a DIV 10 OHSC after 25 minutes of 200µM 4-AP perfusion.
Ictal and inter-ictal bursting patterns are observed, characteristic of the refractory model
of seizures described by Albus et al. (Albus et al., 2008). Traces were high pass filtered
offline at 10Hz.
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Figure 6

64

Figure 7 – Propidium iodide uptake following 4-AP treatment
4-AP causes cell death, indicated by the red staining of Propidium Iodide (PI). PI uptake
is greatly increased in OHSCs following treatment with 24 hours of 4-AP (bottom panels)
compared to control slices (top panels). Staining is especially notable in the pyramidal
and granule cell layers of OHSCs.
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Figure 7

66

Figure 8 – Bar graph of PI staining
Bar graph representing the densitometric analysis of PI uptake in OHSCs following 4-AP
injury. There is significantly more cell death in OHSCs that have undergone 4-AP
treatment than controls at the 24 hour time point (*p<0.05). However, these differences
are not significant at 5 days or 14 days following the injury, indicating that most of the
cell death occurs acutely.
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Figure 8
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Figure 9 – 4-AP treatment causes long term seizure activity
Field potential recording from CA3 14 days after 4-AP injury reveals a significant
number of OHSCs that display seizure activity. An in vitro seizure is defined as an
electrographic event with an abrupt onset of a high amplitude burst of rhythmic activity
superimposed on a field depolarization shift that lasted 3 s, during which the waveforms
evolved over time and terminated abruptly

69

Figure 9
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Figure 10 – Bar graph of seizure rates
Bar graph representative of the percentage of OHSCs displaying spontaneous recurrent
epileptiform discharges (SREDs, seizures) in each treatment group. Fourteen days after
4-AP injury, 62% of treated cultures showed seizure activity compared to 30% of
controls (p=0.006, z-test).
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Figure 10
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D. Discussion

We have successfully cultured and maintained viable organotypic hippocampal
slice cultures in our laboratory. In the first part of this experiment, we established that
OHSCs in our hands would acutely respond to 4-AP as previously shown in the literature
(Albus et al., 2008). It was important to establish that our culture system responded to 4AP at DIV 10 to demonstrate that K+ channels were functional in our OHSCs and could
therefore respond to the drug injury. Albus et al. recently demonstrated that acute 4-AP
treatment in OHSCs yields a model of pharmacoresistant epilepsy. They found that
tonic–clonic seizure-like events induced by low magnesium or by 4-aminopyridine, are
refractory to standard antiepileptic drugs such as valproic acid, carbamazepine,
phenytoin, phenobarbital and 1,4-benzodiazepines (Albus et al., 2008). Though the acute
effects of 4-AP treatment are well studied, the long term physiological consequences
were unknown in an OHSC model.
We therefore utilized 4-AP to induce a longer, status epilepticus like injury. The
addition of 200 M 4-AP to culture media for a 24 hour period led to a significant amount
of cell death acutely following the injury period. However, cell death was not
significantly different from controls in the time periods after the injury period (5 and 14
days). The pattern of cell death appeared to mostly occur in the glutamatergic cells in the
pyramidal cell and dentate granule cell layers, though future immunohistochemical
studies will have to be carried out to confirm cell type. However, this follows the pattern
of cell death observed in animal models of SE (Poirier et al., 2000). Our temporal
specific finding also agrees with the periods of cell death seen in other models of
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acquired epilepsy. In the pilocarpine rat model of AE, there is a 10% loss of cells in the
first week after pilocarpine injury, but there is no further cell death during the period of
epileptogenesis that follows (Raza et al., 2004). In the low magnesium model of acquired
epilepsy in primary hippocampal neuronal cultures, our laboratory has demonstrated that
approximately 30% of the cells die during the status epilepticus injury, but there is no
significant cell death during the period of epileptogenesis (Deshpande et al., 2007c).
Following injury with 4-AP, we observed a significant increase in spontaneous
seizure activity in OHSCs that underwent 4-AP treatment, with 62% of cultures
displaying seizure activity in the CA3 region. This is significantly higher than what has
been reported in OHSCs treated with kainic acid in which 29% of OHSCs displayed
seizures in the dentate gyrus (Bausch and McNamara, 2004) However, in our
experiments, we also noted a high percentage of control OHSCs that showed spontaneous
seizure activity. Though it has been reported that OHSCs in long term culture develop
spontaneous seizures, our observation of a 30% seizure rate at DIV 24 is equivalent to
other reported seizure rates at DIV 40 (Bausch and McNamara, 2004). This may be
explained by the fact that we recorded from the CA3 region, whereas previous studies
have examined the seizure-resistant dentate gyrus. These discrepancies may also be due
to our recording protocol for PI fluorescence. Studies have shown that PI is not
neurotoxic and can be suitable to maintain in long term culture (Kristensen et al., 2007),
but in our protocol, OHSCs were out of the incubator for extended periods during PI
recording while each slice in the 6 well plate was imaged, which could have inadvertently
increased OHSC injury. However, the significant difference in seizure activity between
control and 4-AP treated OHSCs cannot be solely attributed to the PI protocol. We
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therefore conclude that treatment with 4-AP for 24 hours acted as an epileptogenic insult
in our OHSC model.
Slice cultures have been utilized to induce excitability using various
pharmacological manipulations. McBain et al (McBain et al., 1989) utilized the roller
tube method of culture and found epileptiform activity characteristic of both interictal and
ictal events in intracellular recordings in the absence of manipulation in long-term
cultures (up to 12 weeks). They concluded that long-term culturing in this manner lead to
alterations in the balance of excitatory and inhibitory synaptic activity (McBain et al.,
1989). More recently, Bausch and McNamara (Bausch and McNamara, 2000) have
extensively studied granule cell hyperexcitability in OHSCs cultured on membranes via
the interface method (Stoppini et al., 1991). They found that long-term culturing in this
method also led to excessive seizure activity in granule cells. At 40-60 days in vitro, 22%
of the cultures displayed electrographic seizures. They also did extensive morphological
studies in their OHSCs and found that some dentate granule cells may form direct
reciprocal synaptic connections with neurons in all hippocampal subfields including CA1
and that these reciprocal synapses contribute to dentate granule cell hyperexcitability
(Bausch and McNamara, 2000). The formation of reciprocal synapses may also
contribute to the expression of seizures in both control and 4-AP treated OHSCs. Though
it is interesting to note that OHSCs develop seizure activity after long periods in culture
without pharmacological manipulation, it is important to emphasize that our model
utilized cultures much earlier in their in vitro life. Our extracellular recordings took place
at DIV 24, well before others have reported high seizure rates at DIV 40-60.
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Another in vitro model utilizing primary hippocampal neuronal cultures involves
the removal of Mg2+ for excessive activation of the NMDA receptor (Sombati and
Delorenzo, 1995). 4-AP acts by blocking the delayed rectifier type K+ channels, allowing
for excessive neuronal depolarization. Though these two injuries act on different
receptors, they both allow for extended increases in intracellular Ca2+, which is thought to
play an essential role in epileptogenesis (DeLorenzo et al., 2005). Organotypic
hippocampal slice cultures provide a substrate with a complexity between primary
cultures and animal models. Establishing a reliable model of acquired epilepsy in OHSCs
provides an additional mechanism to study the molecular changes that occur during
epileptogenesis while allowing for high-throughput screening of future anti-epileptic and
antiepileptogenic agents. We have successfully established an organotypic hippocampal
slice culture model of spontaneous recurrent epileptiform discharges after cellular injury
by a status epilepticus-like excitotoxic injury. In the 4-AP injury model, most of the cell
death appears to occur acutely after injury. The surviving, but injured cells undergo the
molecular changes that result in expression of seizures following a latent period of
epileptogenesis. This model provides us with a unique, intact hippocampal culture system
in which we can study the cellular and molecular changes that occur after brain injury
and how these changes may lead to acquired epilepsy. The ability to maintain and record
several parameters of excitotoxicity in slice cultures will allow us to further use this
system to evaluate other types of excitotoxic injury and to model and evaluate other
neurotraumas that lead to epileptogenesis.
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CHAPTER 2: AN ORGANOTYPIC HIPPOCAMPAL SLICE
CULTURE MODEL OF EXCITOTOXIC INJURY INDUCED
SPONTANEOUS RECURRENT EPILEPTIFORM DISCHARGES

A. Introduction
The association between stroke and epilepsy is well recognized, but it is not well
understood. Stroke is one of the most common neurological conditions, affecting over
half a million Americans per year (Taylor et al., 1996) and is a leading cause of acquired
epilepsy (AE), most commonly in the elderly (Annegers et al., 1996; Armstrong et al.,
2009; Herman 2002). The development of AE after a stroke has been shown to increase
both the morbidity and mortality of the stroke patient (Menon and Shorvon 2009). Thus it
is important to prevent the development of AE after stroke. Despite this, the mechanisms
underlying the development of epilepsy (epileptogenesis) following stroke-like injury are
poorly understood.
Stroke refers to the brain injury that occurs following cerebral ischemia (Sharp et
al., 1998). It has been suggested that acute ischemia increases extracellular concentrations
of glutamate (Buchkremer-Ratzmann et al., 1998), reduces GABAergic function, and
causes functional or structural impairment of GABAergic interneurons (Menon and
Shorvon 2009). In addition, injury from stroke also causes selective cell death and
apoptosis, changes in membrane potential properties, mitochondrial changes, receptor
changes, deafferentation or collateral sprouting (Menon and Shorvon 2009). Together
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these impaired functional and structural relationships may lead to epileptogenesis- a
process that causes a permanent neuronal plasticity change in previously normal brain
tissue, leading to the onset of spontaneous recurrent epileptiform discharges (SREDs)
(DeLorenzo et al., 2007). Certainly, this period of epileptogenesis represents an important
clinical time-frame wherein intervention may be able to inhibit the plasticity changes that
lead to the development of seizures.
Development of an in vivo model of stroke-induced AE has met limited success
(Karhunen et al., 2005). Our lab has utilized the in vitro hippocampal neuronal culture
model of stroke-induced AE (Sun et al., 2001; Sun et al., 2004). The in vitro model
utilizes glutamate exposure to produce an injury similar to that seen secondary to
ischemic stroke. Subsequent to injury, surviving neurons manifest SREDs analogous to
epileptic seizures (Sun et al., 2001; Sun et al., 2004). While this model provides insight
into some of the molecular mechanisms involved in epileptogenesis following stroke, it is
limited by lack of normal anatomical morphology and circuitry that is important in
excitatory feedback in the brain. In contrast, animal models provide proper morphology
and neuronal feedback, but they are often time consuming and cost restrictive for use in
rapid screening of novel therapeutic compounds. Some of these limitations could be
overcome while still using an in vitro system by utilizing organotypic hippocampal slice
cultures (OHSCs). OHSCs have been shown to manifest intact neuronal morphology,
cellular and anatomical relations and network connections (Noraberg et al., 2005;
Sundstrom et al., 2005; Zimmer and Gahwiler 1984). OHSCs have been used to study the
acute physiological effects (Albus et al., 2008; Wahab et al., 2010) and some of the
morphological changes that occur following excitotoxic injury (Routbort et al., 1999;
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Thomas et al., 2005). Glutamate toxicity is an important aspect of the ischemic cascade
(Buchkremer-Ratzmann et al., 1998). OHSC models have also established similarities in
cell death patterns in oxygen glucose deprivation and glutamate injury, suggesting
NMDA mediated cell death in both injuries (Lipski et al., 2007, Noraberg et al., 2005).
However, a thorough characterization of the physiological changes that occur after
excitotoxicity particularly its effect on seizure genesis has not been explored.
In this paper, we describe development of an OHSC model of glutamate injury
induced AE. Our novel model utilizes a glutamate injury paradigm to induce a stroke-like
injury in OHSCs (Lipski et al., 2007). After a period of epileptogenesis, field potential
and intracellular recordings revealed expression of SREDs, the in vitro correlate of
“seizures”, in glutamate treated slices as compared to untreated sham control slices.
Pharmacological studies using standard anticonvulsant drugs have also been described.

B. Methods
Organotypic hippocampal slice culture preparation
Slice cultures were prepared using the method of Stoppini et al. (Stoppini et al.,
1991), as previously reported by (Schanuel et al., 2008). All animal use protocols are in
strict accordance with the National Institute of Health guidelines and are approved by the
International Animal Care and Use Committee of Virginia Commonwealth University.
Postnatal day 8 (P8) Sprague-Dawley rat pups (Harlan, Frederick, MD, USA) were
deeply anesthetized with isoflurane and decapitated. The brains were removed, and
hippocampi were dissected out and cut into 350-µm transverse sections using a McIlwain
tissue chopper (Brinkmann Instruments, Canada) and placed into Hank’s balanced salt
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solution [HBSS – Gibco BRL (Invitrogen, Carlsbad, CA, USA)] supplemented with 0.5%
sucrose and 1% penicillin-streptomycin. The middle four to six slices of each
hippocampus, including part of the entorhinal cortex, were placed onto tissue culture
membrane inserts (Millipore, Bedford, MA) in a 6-well tissue culture dish containing
medium consisting of 50% minimum essential medium, 25% horse serum and 25%
HBSS, 1% penicillin-streptomycin [all from Gibco BRL (Invitrogen, Carlsbad, CA)] and
supplemented with 36 mM glucose, and 25 mM Hepes (Sigma, St. Louis, MO, USA) (pH
7.2). Cultures were maintained at 37°C under room air +5% CO2. After 1 day in culture,
culture medium was replaced with fresh medium containing no antibiotics. Culture
medium was replaced two times a week thereafter.

Glutamate injury
After 21 days in vitro (DIV21), slice culture media was removed and replaced by
media containing 3.5mM glutamate and cultures were returned to the incubator for a
period of 35 minutes (Lipski et al., 2007). Glutamate containing media was then removed
and slice cultures were washed with HBSS at 37°C two times before returning to normal
media. Control slices received normal media (without glutamate) during the 35 minute
time period, followed by washing with HBSS twice before returning to normal media.

Neuronal death assay
Delayed neuronal death was assessed 24 and 72 hours after glutamate treatment
by measuring uptake of the fluorescent dye Propidium Iodide (PI, Sigma), using
established procedures (Lipski et al., 2007; Pomper et al., 2001). Greater PI uptake
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indicates greater cell death. Cultures were exposed to 2 µM PI for 4 hours in normal
culture media. Before recording dye uptake under fluorescent light, a phase contrast
picture of each slice was taken so that orientation in the field could be maintained in
subsequent recordings at 24 and 72 hours. Dye uptake was recorded on an Olympus
CK40 inverted microscope coupled to a QColor 3 camera and QCapture software
(Olympus, Center Valley, PA). All optical parameters (illumination aperture, neutral
density filters etc.) as well as the camera exposure time and electronic gain, were
standardized and kept constant. The fluorescent signal was measured densitometrically
using the Image-J software (NIH). The perimeter of each slice was outlined (identified in
phase contrast image) and the mean pixel value (0–255) was recorded and converted to a
scale of 0-100. All measurements were made after subtracting background fluorescence
(region positioned immediately outside the culture). Cell death was expressed as a
percent increase of mean pixel value of date matched controls. To assess differential cell
death by region, cell regions were identified and circled as regions of interest in the phase
contrast image. Propidium iodide staining was then measured densitometrically in each of
the 3 cell regions (CA1, CA3, DG). As in whole hippocampus recordings, cell death was
expressed as a percent increase of mean pixel value of each cell region in age datematched controls.

Field potential recording
At DIV 30-33, a portion of the tissue culture insert membrane containing a single
cultured slice was placed into an interface slice recording chamber (Harvard Apparatus,
Holliston MA) mounted on a vibration table and viewed through a dissecting microscope
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(Diagnostic Instruments, Sterling Heights, MI). Slice cultures were perfused (2–3 ml/min)
with artificial cerebrospinal fluid (aCSF) composed of (in mM) 120 NaCl, 3.5 KCl, 1.3
MgSO4, 2.5 CaCl2, 1.25 NaH2PO4, 25.6 NaHCO3, and 10 glucose, equilibrated with 95%
O2-5% CO2. Recording pipettes were pulled on a Flaming Brown P-80 PC Micropipette
puller (Sutter Instrument Co, Novato, CA) filled with 3.5 M NaCl for extracellular
recordings to achieve a resistance of 2-4 MΩ. Data were collected with an AxoClamp 2B
(Molecular Devices, Union City, CA) recording amplifier and FLA-01 Bessel filter unit
(Cygnus Technologies, Inc, Delaware Water Gap, PA) and pCLAMP 9.0 software
(Molecular Devices). After a 15 minute equilibration period, field potentials were
recorded at 34°C in the CA3 pyramidal cell layer. If spontaneous activity was not
observed in the first few minutes, slices were tested for viability by hilar stimulation (0.3ms square pulse, 0.03 Hz, 50–150 µA) using a bipolar concentric electrode (FHC, Inc.,
Bowdoin, ME) and a stimulator (World Precision Instruments, Sarasota, FL). Slices were
considered acceptable if stimulation elicited an action potential spike that immediately
followed the stimulus artifact with a response threshold 150 µA (Bausch and McNamara
2000; Bausch et al., 2006). Neither the amplitude of the spike nor the shape of the
waveform was used as criterion for acceptable recordings. Each slice culture was
recorded at 2 minute intervals (2 minutes on, 2 minutes off) over a 20 minute time period,
for a total of 10 minutes of recorded activity. Recordings were scored for seizure events
by two separate individuals who were blinded to the treatment group.

Intracellular recording
Whole-cell current-clamp recordings were performed on visually identified
pyramidal neurons in the CA3 region of OHSCs (one cell per slice). A portion of the
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culture membrane containing a single OHSC was excised and transferred to a recording
chamber mounted on a Axioskop 2 FS Plus upright microscope 9 (Carl Zeiss, Inc.,
Thornwood, NY), equipped with an IR/DIC camera. Slices were perfused at 1-2ml/min
with aCSF using a Dynamax peristaltic pump (Rainin, Oakland CA). Patch
microelectrodes had a resistance of 2 to 4 M resistance when filled with an internal
solution of (in mM) 140 K+ gluconate, 1MgCl2, 10 HEPES, 1.1 Ethylene glycol-bis (ßaminoethyl ether)-N, N,N',N'-tetraacetic acid (EGTA), 4 Na2 ATP, 15 Tris
Phosphocreatine, pH 7.2 with NaOH and osmolarity adjusted to 310 mOsm with sucrose.
Recordings were obtained using MultiClamp 700B amplifier in current clamp mode. Data
were digitized by a DigiData 1440A, low-pass filtered at 2 kHz, sampled at 10 kHz and
recorded using pClamp 10.0 software. Cells were acceptable for recording if they
maintained a membrane potential of -40mV or more hyperpolarized and were able to
spike when a current pulse was injected. Cells were omitted if series resistance was not
stable within 15% during recording.

Drug perfusion
To determine efficacy of AEDs in this model, phenobarbital, phenytoin, and
ethosuximide (all from Sigma) were added to the aCSF during perfusion and field
potential recording at DIV 30-33. Drugs were dissolved as stock solutions and working
solutions were prepared fresh daily. Phenobarbital and ethosuximide stocks were
dissolved in sterile water while phenytoin was dissolved in dimethyl sulfoxide (DMSO).
The final concentration of DMSO in the bath solution was less than 0.01%. Drugs were
perfused for 20 minutes followed by a 20 minute wash out period with aCSF. The order
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of drug perfusion was randomized for each slice. Field potential recording was
continuous for 40 minutes, rather than intermittent as in previous recordings. Drug effect
was analyzed by evaluating average field potential frequency and amplitude for 2 minutes
before drug perfusion began and again in the final 2 minutes of drug perfusion. Drug
effect is expressed as a percent decrease in average field potential frequency and
amplitude during AED perfusion, as compared to the values before drug perfusion.

Data analyses
Data are expressed as mean ± SEM. To determine significance between treatment
groups for neuronal death assays, Mann-Whitney Rank sum or one way ANOVA tests
were employed with a Fisher’s post-hoc where appropriate. For extracellular recordings,
Chi-square analysis or Fisher’s exact test was used. For intracellular recording, Fisher’s
exact test was used to evaluate seizure occurrence, while Mann-Whitney Rank sum and
Student’s t-tests were used to evaluate additional electrophysiological properties. In all
assays, n refers to number of OHSCs. For neuronal death assays, glutamate treated slices
were normalized to control slices harvested from the same animal. For intracellular
recording, 1 neuron was patch-clamped per OHSC. All experiments were performed over
the period of several weeks to months so that the results were representative of multiple
cultures. A P-value < 0.05 was considered significant. Statistical analysis was performed
using SigmaStat 2.0 software and graphs were drawn using SigmaPlot 11 (Systat
Software, San Jose, CA, USA).
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C. Results
Glutamate exposure produced hippocampal neuronal injury
Figure 11a shows PI staining in OHSCs after injury with 3.5 mM glutamate. PI
uptake was measured in optical density units of the whole slice. At 24 hours, glutamate
injured OHSCs showed an increase in PI uptake of 151.17 ± 5.364% (n= 174) of agematched controls (100 ± 3.09%, n= 121, p<0.001, Mann-Whitney Rank sum test). The
increase in PI staining in glutamate treated slices was still significant at 72 hours, with
optical density measurements of 123.5 ± 2.89% (n=154) of controls (100 ± 2.535%,
n=108, p<0.001, Mann-Whitney Rank sum test) (Figure 11b). PI staining displayed that
the glutamate treatment killed some, but not all neurons, producing a mixed population of
live and dead neurons. The CA1 region showed significantly higher cell death than the
dentate gyrus at 24 hours (133.0 ± 3.8% vs. 115.8 ± 2.4%, n=154 for both, p<0.05, one
way ANOVA with a Fisher’s post-hoc analysis), though this effect was not significant at
72 hours (Figure 11c). The CA3 region did not show a significant difference in cell death
when compared to either CA1 or DG at either time point.

Glutamate injury induced alterations in OHSC excitability
To investigate changes in OHSC excitability, we obtained field potential
recordings from the CA3 region of OHSCs 9-12 days after glutamate injury. OHSCs
were first tested for viability by stimulating in the dentate gyrus while recording in the
CA3 cell layer. Representative field potential recordings of control and glutamate treated
OHSCs are shown in Figure 12. Seizure events were defined as the abrupt onset of a high
amplitude burst of rhythmic activity superimposed on a field depolarization shift that
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lasted 3 s, during which the waveforms evolved over time and terminated abruptly
(Bausch et al., 2006; Routbort et al., 1999). Field potential recordings showed seizure
events in 46.25% of glutamate treated OHSCs (n= 80) compared to 7.14% of control
slices (n= 28, p<0.001, Chi-square analysis). OHSCs displaying seizures had an average
of 3.73 ± 0.57 seizure events per 2 minute recording, lasting an average of 14.26 ± 3.11
sec. The average maximal amplitude shift was 0.78 ± 0.14 mV. While some control and
injured slices displayed individual action potentials and brief depolarizing shifts, these
slices were not considered to have seizure events unless the burst of activity occurred for
greater than 3 seconds.

Spontaneous recurrent epileptiform discharges in glutamate-injured OHSCs
To further confirm seizure activity in glutamate treated OHSCs, whole-cell
current clamp methods were employed on CA3 cells in glutamate treated and control
slices. Cells in glutamate treated slices displayed SREDs while cells in control slices did
not (Figure 13). SREDs were defined as a burst of activity with a spike frequency ≥ 3Hz
for durations of ≥ 20 sec (Sun et al., 2001). This electrographic recording is analogous to
electrographic seizures observed with EEG recordings (McNamara, 1994). Cells in
control slices showed spontaneous firing as well, but it did not meet the criteria for a
SRED. SREDs were observed in 43.7% of glutamate treated slices (n=16), compared to
0% of control slices (n=9, P= 0.027, Fisher exact test). Cells in control slices had an
average spike frequency of 0.0637 ± 0.0495 Hz over 257 minutes of recording. Cells
from all glutamate treated slices had an average spike frequency of 0.8406 ± 0.545154 Hz
over 211 minutes. Of those glutamate treated slices that displayed SREDs, average spike
frequency was 1.54384 ± 0.9357 Hz over 105 minutes (P=0.014 compared to control,
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Mann-Whitney Rank Sum Test), with frequencies over 3 Hz during SRED events. The
resting membrane potential of control cells was -63.9 ± 2.8 mV (n=9) and this was not
significantly different from all glutamate treated cells (-59.45 ± 2.5 mV, n=16, p=0.25,
Student’s t-test) or those cells displaying SREDs (-55.1 ± 3.8 mV, n=7, p=0.08, Student’s
t-test). Input resistance was also not significantly different between the two groups
(226.87 ± 21.3 MΩ for control, 258.5 ± 53.3 MΩ for glutamate treated cells (p=0.6,
Student’s t-test).

SREDs lasted for the life of the OHSCs
Field potential recordings were performed at different time points after glutamate
injury to confirm the optimal time of recording. In glutamate treated slices seizure
activity was not observed immediately after the injury, at DIV 21. However, seizure
activity was present at DIV 24, 3 days after injury, in 40% of slices. Seizure activity
continued in approximately 50% of treated slices until DIV 40 (Figure 14). Consistent
with literature findings (Bausch and McNamara, 2000; McBain et al., 1989), control
OHSCs began showing more spontaneous seizure activity as time in culture increased,
with 12.5% showing seizure activity between 34 and 40 days in vitro. At this point in
culture, the expression of spontaneous epileptiform activity is thought to arise from an
alteration in the balance of excitatory and inhibitory synaptic activity, resulting increased
synaptic activity (McBain et al., 1989). Therefore, we established DIV 30-33 as an
acceptable window for field potential recording as there is a significant difference in the
frequency of seizure events in injured and control slices.
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Degree of cell death did not determine development of SREDS
To determine if the varying degree of cell death played a role in the development
of seizure events, we analyzed PI staining in the glutamate treated slices that had been
used in field potential recordings. As shown in Figure 15, slices displaying SREDs
showed a 45.89 ± 11.956% (n=34) increase in PI uptake 24 hours after injury when
compared to matched controls, while slices that did not show seizure activity showed a
48.5 ± 9.231% (n=39) increase. Similarly, at 72 hours, seizing slices maintained a 45.5 ±
9.23% (n=34) increase while non-seizing slices showed a 31.3 ± 7.445% (n=39) increase
over controls. These values are not significantly different (p=0.862 and 0.175,
respectively, Student’s t-test) from one another, suggesting that magnitude of cell death
following initial injury does not play a significant role in the development of seizure
activity in this model. In addition, there was no significant difference in cell death in
individual cell areas among OHSCs that displayed seizure activity and those that did not
(all P>0.198, data not shown).

Phenobarbital and phenytoin but not ethosuximide inhibited epileptiform activity
To better understand the characteristics of the in vitro seizure events, we
employed several standard AEDs to see their effect on seizure activity in this model.
Given the refractory nature of other seizure models in OHSCs, chosen AED
concentrations were slightly higher than equivalent anticonvulsant plasma concentrations
in rats (Albus et al., 2008). Perfusion of phenytoin (200 µM) during extracellular
recording reversibly reduced the amplitude and frequency of the field potential seizure
activity (Figure 16a). After 18 minutes of drug perfusion, phenytoin decreased the field
potential amplitude by 23.4 ± 9.3 % (P=0.045) and frequency by 83.8 ± 4.6% (p<0.001,
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n=4). Phenobarbital (400 µM) also acted as a reversible anti-seizure agent in this model,
though the onset of its action was longer (Figure 16b). Field potential amplitude
decreased by 23.3 ± 8.5% (p=0.035) and frequency decreased by 77.3 ± 12.7%
(p<0.001) following 18 minutes of drug perfusion (n=4). On the other hand,
ethosuximide (1 mM), a T-type, voltage gated calcium channel blocker effective in
treating generalized absence seizures (Rogawski and Porter 1990), had no effect on
seizure activity in this model (Figure 16c). Amplitude (3.7 ± 3.6% decrease) and
frequency (27.6 ± 29.6% increase) remained unchanged (p>0.05, n=4). Thus, the seizure
activity induced by glutamate injury in our model responded to therapeutically relevant
concentrations of anticonvulsants analogous to the setting of generalized tonic clonic and
partial complex seizures (Macdonald and Kelly 1995).
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Figure 11. A. Propidium Iodide uptake - Propidium Iodide (PI) uptake in OHSCs
following 35 minute treatment with 3.5mM glutamate. PI staining indicates increased cell
death in glutamate treated slices as compared to controls at both 24 and 72 hours
following treatment. Note that significant cell death is observed in the CA1 cell region.
(4X magnification). B. Comparison of PI uptake - Quantification of PI uptake in
OHSCs at 24 and 72 hours after injury, expressed as a percent change from control. PI
uptake was measured as mean optical density of the whole slice and normalized to agematched controls. PI staining indicated a significant increase in cell death at both 24
(n=121, 174 for control and glutamate treated, respectively) and 72 hours (n=108, 154 for
control and glutamate treated, respectively) after glutamate treatment (*p<0.001, MannWhitney Rank Sum test). C. PI uptake by cell region - At 24 hours, cell death is
significantly higher in the CA1 cell region than it is in the dentate gyrus (DG) (*p<0.05,
Kruskall-Wallis One Way ANOVA On Ranks). The CA3 region did not have a
significant difference in PI uptake from either the CA1 or DG. At 72 hours, there is no
significant difference in PI uptake between cell regions. (n=154)
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Figure 12. Extracellular recordings - Representative extracellular field potential
recordings of CA3 cell layer of OHSCs at DIV 30. A. Control - Control OHSCs do not
display seizure activity in aCSF. B. Glutamate treated - Representative field potential
recording from an OHSC that was subjected to glutamate injury at DIV 21. Seizure
activity is characterized by repetitive bursts of activity that last for longer than 3 seconds,
changes over time and terminates. All vertical bars = 0.5mV
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Figure 13. Intracellular recording - Representative intracellular whole cell current
clamp recordings of CA3 pyramidal cells at DIV 30. A. Control - Cells from control
slices did not display repetitive bursting (n=9) B. Glutmate treated - Cells from
glutamate treated slices displayed spontaneous recurrent epileptiform discharges
(SREDs), similar to activity seen in extracellular field potential recordings. SREDs were
observed in 43% of slice cultures following glutamate injury at DIV 21 (n=16).
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Figure 14. Development of seizures after injury - After glutamate injury (solid line), a
significant percentage of OHSCs display seizure activity in field potential recordings as
compared to age matched controls (dashed line). This change is long lasting and was
observed up to 40 days in vitro. Within hours of injury (DIV 21), OHSCs did not display
seizure events in either the control or injured groups (n=6 each). Between 3 and 8 days
after injury (DIV 24-29), 40% of injured OHSCs and 0% of controls displayed seizure
events (n=10 each, *p<0.05, Fisher’s exact test). In our established experimental time
frame, DIV 30-33, we observed seizure events in 46.25% of glutamate injured OHSCs
and 7.14% of controls (n=80, 28, **p<0.001, Chi-square analysis). By DIV 34-40,
seizure events were observed in 50% of injured slices and 12.5% of controls (n=8, 9).
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Figure 15. Degree of cell death does not determine seizure activity - After glutamate
injury, OHSCs displayed slightly varying degrees of cell death. However, the degree of
cell death observed does not appear to play a role in the development of seizure activity.
OHSCs were evaluated for cell death at 24 and 72 hours after glutamate injury on DIV
21. They were returned to the incubator until field potential recording at DIV 30-33.
OHSCs that did not display seizure activity (white bars, n=39) did not significantly differ
in PI uptake from OHSCs displaying seizures (gray bars, n=34).
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Figure 16. Standard AEDs are effective at blocking seizure activity - Representative
field potential recordings of the effect of standard anti-epileptic drugs on seizure activity
in glutamate treated slices at DIV 30. A. Phenytoin (200 M) is effective at blocking
seizure activity during a 20 minute perfusion and can be washed out. On average,
phenytoin decreased field potential amplitude by 23.4 ± 9.3 % (P=0.045) and frequency
by 83.8 ± 4.6% (p<0.001, n=4) B. Phenobarbital (400 M) is also effective at blocking
seizure activity during the 20 minute period of perfusion, amplitude decreased by 23.3 ±
8.5% (p=0.035) and frequency decreased by 77.3 ± 12.7% (p<0.001) following 15
minutes of drug perfusion (n=4). C. Ethosuximide (1 mM), is not effective at blocking
seizure activity in glutamate injured OHSCs (p>0.05, n=4). All vertical bars = 0.1mV
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D. Discussion
The experiments in this study document a novel model of epileptogenesis in
OHSCs following glutamate injury. Similar to the excitotoxic injuries associated with
both ischemic and anoxic stroke events, glutamate injury in this model produced a mixed
population of neurons characterized by both cell survival and cell death. As suggested by
our initial hypothesis, neurons that survived the glutamate exposure become the substrate
for the development of epileptogenesis as indicated by increased excitability of the CA3
cell layer in a significant number of OHSCs. The OHSC model of glutamate injury
induced spontaneous seizure events may provide insights into the development of stroke
induced AE. It also offers a powerful tool to screen potential pharmacological agents to
treat seizures and develop therapeutic interventions to prevent the development of AE
after stroke.
The seizure events seen in extracellular recordings expressed many characteristics
of overt electrographic epileptic seizures. Seizure events started and terminated
spontaneously and were synchronized in nature, as they represented a population of
synchronized neurons (Figure 12). The seizure events produced by excitotoxic glutamate
injury manifested larger spike amplitude than would be seen if the activity originated
from a single neuron, suggesting that the activity occurred in a group of neurons. The
typical seizure pattern observed in OHSCs after glutamate injury also included an abrupt
onset of activity superimposed on a large field potential shift, consistent with the classic
paroxysmal depolarizing shift associated with electrographic seizure discharges in both in
vitro and in vivo models of epilepsy (Bausch et al., 2006; Dichter and Ayala 1987).
Finally, the seizures produced by glutamate injury responded to the anticonvulsant drugs
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phenobarbital and phenytoin, but not to ethosuximide (Figure 16). These results
demonstrated that OHSCs subjected to injury by glutamate exposure could be
transformed into neuronal networks manifesting seizures for the life of the culture,
producing an in vitro model of epilepsy.
Various studies of OHSCs have confirmed that cells develop and mature similar
to age-matched cells in vivo (Bahr et al., 1995, Stoppini et al. 1991). In this respect,
OHSCs are often used at times comparable to the appropriate in vivo age. Our OHSCs are
cultured at P8 and injured at DIV 21, thereby showing the equivalent cellular maturity of
young adult rats at P29. OHSCs from P8 pups have been shown to develop mature
synaptic properties within a few days in culture (Muller et al., 1993). In addition, OHSCs
have been shown to respond to seizure inducing stimuli over a wide range of time points
anywhere from 7-56 days in culture (Albus et al., 2008). We therefore believe our slice
cultures are at an appropriate age to respond to a glutamate injury at DIV 21.
Organotypic hippocampal slice cultures have been utilized in many models of
excitotoxicity, including kainic acid (Routbort et al., 1999), NMDA (Ring et al., 2010),
and oxygen glucose deprivation injuries (Lipski et al., 2007). However, few of these
studies have examined the long-term physiological changes that occur in OHSCs after
excitotoxic injury, thereby exploring their potential as a model of acquired epilepsy.
Recently, Bausch and McNamara (Bausch and McNamara 2004) used a kainic acid
injury paradigm in OHSCs and found no significant difference in seizure rates from
controls when recording from granule cells in physiological buffer 30 days after injury.
They were however, able to show that the granule cells were more hyperexcitable and
there was considerable mossy fiber sprouting in the injured slices. Various other studies
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have used excitotoxic injuries to study neuroprotective agents and morphological changes
(Boscia et al., 2006; Cho et al., 2007; Lipski et al., 2007; Ring et al., 2010; Routbort et
al., 1999; Thomas et al., 2005). Our model takes this a step further by characterizing the
physiological changes after an excitotoxic injury with glutamate. A study by Lahtinen et
al. (Lahtinen et al., 2001) utilized a higher concentration of glutamate (10 mM) to
examine acute electrophysiological consequences of glutamate injury in OHSCs. Within
2 hours of the injury, they found increased hyperexcitability in the CA3 cell region. In
addition, they reported attenuation of cell death with TTX following glutamate injury,
indicating that some cell death during the initial 24 hour period may be caused by
neuronal excitability following the initial injury. Indeed, clinical and in vivo studies have
shown that seizures often occur acutely following an ischemic injury (Menon and
Shorvon, 2009, Karhunen et al., 2006), but this does not necessarily lead to
epileptogenesis and acquired epilepsy. This would suggest that the post-insult activity
observed by Lahtinen et al. is not necessarily indicative of chronic epileptogenesis. In
contrast, our study employs a more moderate glutamate injury (3.5mM glutamate for 35
minutes) and we examine cell death at both 24 hours and 72 hours. We establish that cell
death subsides following the 24 hour period, as the PI uptake is significantly decreased at
72 hours. In addition, we examine epileptogenesis in OHSCs 9-12 days following
glutamate injury indicating long lasting changes in neuronal excitability following
glutamate injury. It is important to stress this issue, since our study is the first
demonstration of the development of spontaneous recurrent epileptiform discharges
(epilepsy) in the OHSCs and represents the first model of post injury acquired “epilepsy”
in this model.
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Our model utilizes glutamate as a mode of excitotoxicity, as excessive glutamate
concentration is an important aspect of the ischemic prenumbra in stroke (Davalos et al.,
1997). The involvement of glutamate in epileptogenesis has been implicated in whole
animal, (Croucher et al., 1988; Croucher and Bradford 1990; Rice and DeLorenzo 1998)
slice, (Anderson et al., 1990; Stasheff et al., 1989) and cell culture (Sombati and
Delorenzo 1995; Sun et al., 2001) models of epilepsy. To induce epileptogenesis, these
models all used continuous neuronal spiking produced by seizures, (Rice and DeLorenzo
1998) repeated high-frequency excitation (Croucher et al., 1988; Croucher and Bradford
1990; Stasheff et al., 1989), or low extracellular magnesium environments(Anderson et
al., 1986; Sombati and Delorenzo 1995) while only one used a glutamate-induced
prolonged, reversible depolarization as used in this study (Sun et al., 2001; Sun et al.,
2004). Many of these models have implicated activation of the N-methyl-D-aspartate
receptor (NMDAR) for epileptogenesis (Croucher et al., 1988; Croucher and Bradford
1990; DeLorenzo et al., 1998; Rice and DeLorenzo 1998; Stasheff et al., 1989).
Interestingly, epileptiform discharges have also been produced by growing OHSCs in
culture in the presence of tetrodotoxin (TTX) to block activity or D(–)-2-amino-5phosphonopentanoic acid (D-APV) to block NMDAR activation (Bausch et al., 2006).
Removal of these agents resulted in the expression of seizure-like activity (Bausch et al.,
2006). This distinctly different culture model uses the inhibition of glutamate receptors to
induce hyperexcitability. Control OHSCs displayed a low occurrence of seizures,
possibly as a result of collateral synaptic connections that are known to form after long
term culture of hippocampal tissue (Bausch and McNamara 2000; McBain et al., 1989).
Although the mechanism producing hyperexcitability in this model has not been fully
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delineated, it has been shown that inhibition of glutamate receptors in neurons in culture
produces alterations in NMDAR subunit expression that are regulated by synaptic activity
during development (Hoffmann et al., 2000; Yashiro and Philpot 2008). It is possible that
alterations in NMDAR subunit expression may underlie the development of
hyperexcitability in this model. Though glutamate exposure may induce changes in
receptor subunit expression in the glutamate injury–induced epileptogenesis model, these
potential changes probably occur through a separate mechanism. It will be interesting to
investigate the mechanism of glutamate injury-induced epileptogenesis in future studies.
The potential role of selective neuronal death in glutamate injury–induced
epileptogenesis requires further investigation, especially in light of the fact that inhibitory
neurons are typically less vulnerable to excitotoxicity than excitatory neurons (Tecoma
and Choi 1989). Although differential cell death may affect the balance between the
number of inhibitory and excitatory neurons, resulting in a larger number of surviving
inhibitory neurons, (Tecoma and Choi 1989) the glutamate-induced injury produced
"epilepsy" in the OHSCs despite the potential alterations in neuronal subpopulations. Our
experiments suggest that the severity of injury is not a large factor in epileptogenesis, as
there was no difference in the degree of cell death in those OHSCs that developed
seizures and those that did not (Figure 15). Further studies are needed to determine the
role of selective cell death in this model. In addition, the possible roles of gap junctions
(Dudek et al., 1998), ischemia-induced alterations in second-messenger systems, and
gene changes (Morris et al., 2000) in mediating epileptogenesis represent important future
directions for research that can be conveniently studied in this system.

106

The association between stroke and epilepsy has been demonstrated clinically, and
stroke is the most common cause of acquired epilepsy in adults (Hauser et al., 1991).
However, the mechanisms by which cerebral ischemia initiates epileptogenesis are not
understood. The glutamate injury produced in this model of epileptogenesis resembles
some of the phenomena associated with stroke. Increases in extracellular glutamate,
(Bullock et al., 1995; Davalos et al., 1997) excitotoxic delayed neuronal death (Choi
2000) associated with the ischemic penumbra (Dirnagl et al., 1999), and a delayed period
of epileptogenesis are all present in this model. To our knowledge, this study
demonstrates, for the first time, spontaneous, recurrent, epileptiform activity in
organotypic hippocampal slice cultures induced by glutamate injury. This model of
glutamate injury–induced epileptogenesis may offer new insights into the development
and maintenance of the epileptic condition after a neurological trauma such as stroke and
therefore may provide therapeutic strategies to develop both novel anti-epileptogenic and
anticonvulsant agents to prevent stroke-induced epilepsy.
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CHAPTER 3: CB1 RECEPTOR CHANGES AFTER GLUTAMATE INJURY IN
ORGANOTYPIC HIPPOCAMPAL SLICE CULTURES

A. Introduction
Stroke is one of the most common neurological emergencies, affecting over half a
million Americans per year (Taylor et al., 1996) and it is a leading cause of acquired
epilepsy (AE) among the elderly. Many of the physiological mechanisms surrounding
stroke are well studied, but the molecular changes that occur in the brain during the
development of epilepsy, a process known as epileptogenesis, are not widely understood.
Acquired epilepsy is known to develop after brain injuries such as traumatic brain injury,
status epilepticus, or CNS infection, as well as stroke. Several in vitro (Sombati and
Delorenzo, 1995; Sun et al., 2001) and in vivo (Cavalheiro et al., 1991; Karhunen et al.,
2005; Racine, 1972) models of acquired epilepsy have been developed to study the
molecular events that occur during epileptogenesis. Our laboratory has utilized the rat
pilocarpine model of acquired epilepsy to extensively study changes in the
endocannabinoid system in AE (Falenski et al., 2007; Falenski et al., 2009; Wallace et
al., 2001; Wallace et al., 2002; Wallace et al., 2003).
It’s been reported in the scientific literature for several decades that cannabinoids
have anticonvulsant properties (Karler and Turkanis, 1981). More recently, these
anticonvulsant effects have been demonstrated to be cannabinoid type I (CB1) receptor
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mediated (Wallace et al., 2003). Our laboratory has utilized the rat pilocarpine model of
AE to show that endocannabinoid tone regulates seizure frequency and duration via a
CB1 receptor mechanism. The CB1 receptor is the most abundant G-protein coupled
receptor in the brain and several studies have shown a significant upregulation in CB1
protein in epileptic tissue (Chen et al., 2003; Falenski et al., 2007). Recently, our
laboratory has utilized the rat pilocarpine model of AE to further investigate the cellular
distribution of CB1 upregulation in epileptic animals (Falenski et al., 2007). Interestingly,
in addition to an overall upregulation of CB1 protein in the epileptic hippocampus, studies
also revealed a unique redistribution of CB1 receptor histology whereby CB1 receptor
density actually increased in the stratum oriens, stratum radiatum and outer molecular
layer of the dentate gyrus and decreased on the CA1 and CA3 pyramidal cells and inner
molecular layer of the dentate gyrus (Falenski et al., 2007). These findings suggest a
possible compensatory mechanism after the development of epilepsy by increasing
cannabinoid tone on excitatory synapses and decreasing it on inhibitory synapses, thereby
controlling seizure severity.
These fascinating findings require further study as the possibility of
pharmacological manipulation of CB1 receptors may hold keys to the prevention of
acquired epilepsy or for the control of seizures. However, animal studies of this
magnitude are costly and labor intensive, so the development of an organotypic
hippocampal slice culture (OHSC) model of acquired epilepsy would be much better
suited to high throughput screening and evaluation of changes in the endocannabinoid
system. In addition, OHSCs have been utilized in several studies involving the
physiological signaling of endocannabinoids (Lafourcade et al., 2009) and the
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neuroprotective role of various cannabinoid compounds (Khaspekov et al., 2004; Kreutz
et al., 2009), but not until recently has the molecular distribution of the CB1 receptors
been fully characterized in OHSCs. A recent study of the distribution of CB1 and mGlu1a
receptors in OHSCs that had been in culture for 14 days found that the pattern of CB1
distribution was similar to what is observed in healthy adult animals (Boscia et al., 2008).
This study confirmed that the OHSC system is a valid model to further explore the
molecular changes of the endocannabinoid system after an injury.
Our recent development of a stroke-like injury model of AE in OHSCs (Chapter
2) provides an ideal model to compare the changes of CB1 receptor expression to those
seen in well established animal models. This study was initiated to examine the effects of
glutamate injury on CB1 receptor expression in order to compare these effects to other
established models of acquired epilepsy, and further validate the use of OHSCs in
studying the molecular changes associated with epileptogenesis. Western blot and
immunohistochemical analyses were used to examine CB1 receptor expression in OHSCs
after glutamate injury, establishing that they do, indeed show similarities in CB1 receptor
changes as those observed in in vivo models.

B. Methods
Organotypic hippocampal slice culture preparation
Slice cultures were prepared using the method of Stoppini et al. (Stoppini et al.,
1991), as previously reported by (Schanuel et al., 2008). All animal use protocols are in
strict accordance with the National Institute of Health guidelines and are approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University.
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Postnatal day 8 (P8) Sprague-Dawley rat pups (Harlan, Frederick, MD, USA) were
deeply anesthetized with isoflurane and decapitated. The brains were removed, and
hippocampi were dissected out and cut into 350-µm transverse sections using a McIlwain
tissue chopper (Brinkmann Instruments, Canada) and placed into Hank’s balanced salt
solution [HBSS – Gibco BRL (Invitrogen, Carlsbad, CA, USA)] supplemented with 0.5%
sucrose and 1% penicillin-streptomycin. The middle four to six slices of each
hippocampus, including part of the entorhinal cortex, were placed onto tissue culture
membrane inserts (Millipore, Bedford, MA) in a 6-well tissue culture dish containing
medium consisting of 50% minimum essential medium, 25% horse serum and 25%
HBSS, 1% penicillin-streptomycin [all from Gibco BRL (Invitrogen, Carlsbad, CA)] and
supplemented with 36 mM glucose, and 25 mM HEPES (Sigma, St. Louis, MO, USA)
(pH 7.2). Cultures were maintained at 37°C under room air +5% CO2. After 1 day in
culture, culture medium was replaced with fresh medium containing no antibiotics.
Culture medium was replaced two times a week thereafter.

Glutamate injury
After 21 days in vitro (DIV21), slice culture media was removed and replaced by
media containing 3.5mM glutamate for a period of 35 minutes (Lipski et al., 2007).
Glutamate containing media was then removed and slice cultures were washed with
HBSS at 37°C two times before returning to normal media. Control slices received
normal media (without glutamate) during the 35 minute time period, followed by
washing with HBSS twice before returning to normal media.
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Western blot protocol
Fresh OHSC tissue was harvested on DIV 32 and kept on ice. In order to obtain a
sufficient amount of protein, four OHSCs per sample were homogenized in 50 mM Tris,
pH 7.5, 6 mM EGTA, 320 mM sucrose, 1 mM dithiothreitol, and 0.3 mM
phenylmethylsulfonyl fluoride. Before electrophoresis, whole homogenate samples were
thawed on ice, and protein concentration per sample was calculated using the
MicroBradford reagent system (Bio-Rad, Hercules, CA) quantified using a UV-2101PC
ultraviolet spectrophotometer (Shimadzu, Kyoto, Japan). Samples were balanced to 30 g
protein/gel lane and denatured in beta-mercaptoethanol and loading dye buffer. Samples
were then heated to 90°C for 5 min in a programmable thermal controller PTC100 (MJ
Research, Watertown, MA) and allowed to cool to room temperature before loading onto
a 4-12% Bis-Tris Gel (InVitrogen, Life Technologies, Carlsbad, CA). A colorimetric
molecular mass marker including standards ranging from 10 to 182 kDa (Bio-Rad) was
loaded onto the last lane of the gel to aid in determining protein size. Gels were
assembled into a MiniProtean II Electrophoresis System (Bio-Rad) and resolved for 90
min at constant 200 V in running buffer (Invitrogen). After electrophoresis, gels were
Western blot transferred to nitrocellulose membranes (Millipore Corp., Bedford, MA) for
2 h at 4°C using a Genie transfer apparatus (IDEA Scientific, Minneapolis, MN) at a
constant 100 V in transfer buffer (NuPage Transfer Buffer, Invitrogen). After transfer, the
Western blot was stored in phosphate-buffered saline at 4°C overnight. Membranes were
stained for protein and quantitated for actin protein levels as described previously (Morris
et al., 2000b).
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Immunostaining of the Western blot was performed by first blocking the
membrane in buffer composed of 3% blotting grade blocker (Bio-Rad) and 0.05% Tween
20 in phosphate-buffered saline for 45 min at room temperature. Rabbit (polyclonal) anticannabinoid CB1 receptor primary antibodies generalted to the N-terminus residues 1-77
(N1-77, generously donated by Dr. Ken Mackie, Indiana University) or the C-terminus
residues 461-473 (C 461-473, generously donated by Dr. Maurice Elphick, Queen’s
College) were added to the blocking solution at a concentration of 1:500 and 1:5000
respectively, and the membrane was incubated for 90 min at room temperature. After
primary antibody incubation, the membrane was washed for a total of 15 min (three times
for 5 min each) in phosphate-buffered saline. The membrane was then reblocked in fresh
blocking buffer for 30 min. Anti-rabbit IgG-horseradish peroxidase-conjugated antibody
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was then added to the blocking
solution in a 1:5000 dilution, and the membrane was incubated for a final 45 min.
Western blots were washed (three times for 5 min each) in PBS and incubated for 2 min
in SuperSignal (Pierce Chemical, Rockford, IL) for enhanced chemiluminescent analysis.
Chemiluminescent images were visualized using Kodak X-Omat Blue XB-1 X-ray film
(Eastman Kodak, Rochester, NY) and developed using a Kodak M35A X-Omat
Processor (Eastman Kodak). Film images were digitized using a gel scanner and analyzed
using Image J software (NIH). Using the molecular mass marker as reference, the protein
band was determined to correspond to a mass of around 53 kDa. To normalize protein
levels for each band, Actin was probed as a protein standard. The blot membrane was
then washed with PBS for 30 minutes, followed by re-blocking in blocking buffer. The
membrane was then incubated in Actin primary antibody (1:4000 dilution, Sigma) for 60
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minutes. It was washed in PBS (3x5 minutes) before being incubated in anti-mouse HRP
secondary antibody (1:500), followed by another wash in PBS (3x5 minutes). The
membrane was incubated with SuperSignal for 2 minutes and visualized as above. Actin
bands were visualized at 43kDa. The CB1 protein band densitometry readings were
normalized to their corresponding actin protein band densitometry readings. Previous
studies in our laboratory utilized the specific peptide block for each CB1 antibody in rat
tissues. These studies revealed no immunostaining with addition of the peptide block,
indicating antibody specificity.

Immunohistochemistry
Following field potential recording to assess for seizure activity (see chapter 2),
OHSCs attached to culture membranes were fixed in 4% paraformaldehyde in phosphate
buffered saline (PBS). Fixed cultures were washed as floating samples in 24-well plates
in PBS before blocking and permeabilizing in SuperBlock® blocking buffer (Pierce,
Rockford, IL) containing 0.2% Triton X-100 (SBBT) for 60 min at room temperature,
followed by a 72 h incubation at 4 ºC with polyclonal antibody to the C-terminus of the
CB1 receptor (1:1000) (Egertova and Elphick, 2000) in SBBT. After antibody incubation,
OHSCs were washed four times in PBS containing 0.2% Triton X-100 (PBST). Cultures
were then incubated with anti-rabbit fluorochrome-conjugated secondary antibody
(1:200, Alexa Fluor® 488; Invitrogen Corp., Eugene, OR) in SBBT for 60 min. After four
PBST washes, stained OHSCs were counterstained for 5 min with DAPI (300 nM in
PBS). Stained cultures were washed three times in PBS, mounted on slides, coated with
ProLong Gold® anti-fade agent (Invitrogen Corp., Eugene, OR) and cover slipped.
Control experiments without primary antibodies were carried out in an identical manner.
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Stained cultures were evaluated with a TCS-SP2 AOBS confocal microscope with a 10X
or 40X objective (Leica Microsystems GmbH, Wetzlar, Germany) and lasers with
wavelengths at 405nm (DAPI) and 488nm (FITC). Confocal gain and offset settings were
optimized for each set of tissue so that glutamate treated slices could be normalized to
controls from the same session. Digital images were converted to 16-bit grayscale and
analyzed with Image J software (NIH). Hippocampal regions were visually identified and
circled as regions of interest to analyze individual areas. Glutamate treated areas were
normalized to matched control areas. No-primary control OHSCs were not incubated in
CB1 primary, but were treated the same otherwise.

Statistical analyses.
Results are given as means ± S.E.M. Statistical comparisons were made using
SigmaStat software (Systat software, Chicago IL). The Student's t test was used to
compare control to glutamate treated slices. N refers to number of OHSCs. Graphs were
generated using Sigmaplot 11 software (Systat software). P < 0.05 was considered
significant.

C. Results

There is an overall increase of CB1 receptor protein following glutamate injury

Western blot analysis revealed an overall increase in CB1 receptor protein at DIV
32 in whole homogenates of OHSCs that had been treated with glutamate. The Nterminus and C-terminus antibodies showed similar results when run with the same tissue
samples, therefore the results of all blots were included for analysis, regardless of
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antibody used. Densitometric analysis showed a 128 ± 10.2% increase in CB1 protein in
glutamate treated slices as compared to matched controls (100 ± 5%, P=0.02, Student’s ttest, n=15 each). This analysis reveals an increase in CB1 receptor protein relative to total
protein in each sample in OHSCs that had undergone treatment with 3.5 mM glutamate
(Figures 17 and 18).

CB1 receptors are upregulated in stratum oriens, stratum radiatum, and dentate gyrus

Similar to what has been described in vivo (Falenski et al., 2007) and in vitro
(Boscia et al., 2008), confocal imaging of both control and glutamate treated OHSCs
stained for CB1 receptors revealed a dense plexus of CB1-immunoreactive fibers that
surrounded the immunonegative principal cells. Densitometric analysis of confocal
images obtained from OHSCs stained for CB1 receptors showed a relative overall
increase in several cell regions following glutamate treatment. The CA3 region had
staining that was 1.72 ± 0.19 (n=5) times the relative control OHSCs (1 ± 0.106, p=.036,
n=4, Student’s t-test). Similarly, the dentate gyrus showed a relative increase of 1.38 ±
0.114 (n=7) times the control staining (1 ± 0.05, n= 8, p=0.014, Student’s t-test). The
increase in CB1 density in the CA1 region did not show statistical significance (control, 1
± 0.18, n=4, glutamate, 1.032 ± 0.164, n=5, p=0.97, t-test). However, separate analysis of
the stratum pyramidale, stratum oriens and stratum radiatum revealed a significant
increase in CB1 staining in the stratum oriens of the CA1 region (control, 1 ± 0.09, n=6,
glutamate treated, 1.63 ± 0.290, n=4, p=0.038) and the stratum radiatum of the CA3
region (control, 1 ± 0.06, n=4, glutamate treated, 1.33 ± 0.15, n=5, p=0.032) (Figures 19
and 20). The spread of the granule cells layers in OHSCs (Caeser and Aertsen, 1991)
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made it difficult to delineate layers of the dentate gyrus in all samples, therefore it was
only evaluated as a whole region. OHSC staining also found that the no primary controls
showed minimal staining (Figure 21), indicating specificity of our secondary antibody
and recording parameters.
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Figure 17 – Western blot anaysis of CB1 receptor protein. Whole homogenates of
OHSCs were collected at DIV 32 and analyzed for CB1 receptor protein expression. Two
different CB1 receptor antibodies were used. The N-terminus antibody (a.) and the Cterminus antibody (b.) showed similar results when normalized to actin. Both antibodies
revealed an increase in CB1 protein in samples that had undergone glutamate treatment at
DIV21.
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Figure 17 a.

Figure 17b.
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Figure 18 – There is an increase in CB1 receptor protein after glutamate treatment.
Densitometric analysis showed CB1 protein levels at 128 ± 10.2% of matched controls
(100 ± 5%, P=0.02, Student’s t-test, n=15 each) in glutamate treated slices. This analysis
reveals an increase in CB1 receptor protein relative to total protein in each sample in
OHSCs that had undergone treatment with 3.5 mM glutamate.
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Figure 18
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Figure 19 - Immunohistologic staining of the CB1 receptor at 10X. Immunohistologic
staining for the CB1 receptor using the C-terminus antibody confirms increases in CB1
receptor expression in glutamate treated OHSCs. Confocal microscopy was utilized to
analyze CB1 staining in individual cell areas of the slice cultures. Densitometric analysis
revealed significant increases in CB1 staining in the CA3 and DG regions when compared
to their matched controls.
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Figure 19
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Figure 20 – Confocal imaging of CB1 receptor stained OHSCs – 40X magnification.
Higher magnification of OHSCs stained for CB1 receptor protein show considerable
punctate staining, especially in around cell bodies. When comparing to control (left
panels) OHSCs, the overall increase in CB1 receptor expression is especially apparent in
glutamate treated (right panels) OHSCs at this magnification.
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Figure 20
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Figure 21 – No primary control. To ensure that our fluorescent antibody bound
specifically to the primary antibody, we omitted the primary antibody from the staining
protocol for control OHSCs. The observed fluorescence from the no primary controls was
minimal, indicating specific binding. (10X magnification)
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Figure 21
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D. Discussion

Results from this study demonstrate that the CB1 receptor undergoes changes in
expression in the OHSC model of stroke acquired epilepsy. This supports our hypothesis
that the OHSC model has many similarities to the molecular changes observed in in vivo
models of AE. We have found that the CB1 receptor expression rises to 128% of control
levels following treatment with glutamate, compared to a 183% rise in CB1 receptor
expression observed in the hippocampus of epileptic rats (Wallace et al., 2003).
Glutamate treated OHSCs were collected for protein analysis at DIV 32 at a point when
previous studies (Chapter 2) have shown that approximately 46% of OHSCs would be
displaying seizure activity. Since OHSCs were not tested for seizure activity, we would
expect only about 46% of them would have undergone the changes in CB1 receptor
expression, which would contribute to a less robust change in CB1 receptor expression
than what is observed in animal models. In addition, 7% of control OHSCs at that time
point display seizures, indicating that they may have undergone some of the molecular
changes associated with seizures and possibly have a greater expression of CB1 receptors
than what is observed in control animal tissue. Nonetheless, the upregulation of CB1
receptors observed in this study provides additional support of the utility of the OHSC
model of stroke acquired epilepsy. Stroke acquired epilepsy has been challenging to
model in vivo and current in vitro models have utilized primary hippocampal neuronal
cultures (Sun et al., 2001), which lose normal anatomical connections that play an
important role in the ischemic penumbra. The use of organotypic hippocampal slice
cultures provides a model that is between the organizational complexity of in vitro
primary neuronal cultures and in vivo models.
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Densitometric analysis of immunohistochemical staining of OHSCs showed a
specific increase in the stratum oriens of the CA1 and stratum radiatum of the CA3
region in OHSCs that displayed seizure activity. This finding further supports similarity
to the in vivo pilocarpine model of acquired epilepsy (Falenski et al., 2007; Falenski et
al., 2009). It also supports the hypothesis that the CB1 receptor upregulation observed in
Western blot analysis is specifically located at the glutamatergic terminals. CB1 receptor
distribution in OHSCs under normal conditions has been shown to be similar to what is
observed in normal rats (Boscia et al., 2008). Specifically, previous studies have shown
that the entire hippocampal slice culture is decorated with a dense plexus of CB1immunoreactive fibers that surrounded the immunonegative principal cells. In CA1, an
extensive perisomatic axonal meshwork is evident in the stratum pyramidale (Boscia et
al., 2008). Our immunostaining experiments in control OHSCs showed a similar CB1
profile, with intense staining surrounding the pyramidal cells and decreased staining in
the stratum oriens and radiatum. Following glutamate treatment, seizing OHSCs
displayed significantly increased intensity in CB1 staining in the stratum radiatum and
stratum oriens regions. These results are in agreement with the histological organization
of CB1 receptors in animals with AE. Recent studies from our laboratory suggest a
selective reorganization of CB1 receptors among the excitatory and inhibitory terminals
of the hippocampus (Falenski et al., 2007). Utilizing the rat pilocarpine model of AE,
immunohistochemical studies revealed an increase in CB1 staining of the stratum
radiatum and stratum oriens along with the outer molecular layer of the dentate gyrus in
the epileptic hippocampus. In addition, there was decreased staining of the CA1 and CA3
pyramidal cell layers and inner molecular layer of the dentate gyrus (Falenski et al.,
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2007). These findings further support the hypothesis that the CB1 receptor changes are a
compensatory mechanism to control seizures. An upregulation at glutamatergic terminals,
as observed in these studies, would play a role in dampening excessive neuronal
excitation, whereas a decrease in CB1 at inhibitory terminals would allow for an
increased inhibitory tone. Interestingly, a recent study of the GABAergic terminals in the
mouse pilocarpine model of AE has suggested that there is actually a preferential loss of
GABAergic innervation from CCK-containing basket cells, with an increased
contribution from PV-containing interneurons (Wyeth et al., 2010). This would explain
the decrease in CB1 staining observed at GABAergic terminals without a loss of
GABAergic terminals on CA1 pyramidal cells.

The rat pilocarpine model of AE is not the only model that displays an
upregulation of CB1 receptors as CB1 receptor protein increases have also been noted in
the febrile seizure model (Chen et al., 2003), and kainic acid model. In addition, a recent
study of the hippocampus of the Amazonian, Proechimys, has shown that these rodents
are resistant to developing spontaneous seizures following epileptogenic precipitating
events such as pilocarpine, kainic acid, or kindling (Arida et al., 2005; de Amorim
Carvalho et al., 2003). Evaluation of the Proechimys hippocampus revealed an elevated
level of CB1 receptor protein that is over 1.3 times greater than what is observed in
Wistar rats (Araujo et al., 2010). Another intriguing study of human, sclerotic, epileptic
tissue actually revealed a downregulation of CB1 protein in the epileptic hippocampus
(Ludanyi et al., 2008). These studies provide an interesting view of the role of the
endocannabinoid system in epilepsy. They suggest that the upregulation of CB1 receptors
in animal models of AE might actually be a compensatory mechanism to attempt to
130

control seizure severity after a seizure precipitating event. The studies of human tissue
suggest that this compensatory mechanism does not develop in humans with intractable
epilepsy.
In vivo studies in the rat pilocarpine model of AE have utilized [35S] GTP S
autoradiography to assess the functionality of the CB1 receptor reorganization following
the development of epilepsy. These studies confirmed the functionality of the CB1
receptors in this model (Falenski et al., 2007). An additional advantage to the
development of a OHSC model of AE is that we will readily be able to assess the
functionality of the observed receptor upregulation utilizing electrophysiological
techniques. These studies will further elucidate the physiological changes associated with
an overall increase in CB1 receptor expression after epileptogenic injury.
Acknowledgements: Confocal microscopy was performed at the VCU – Dept. of
Neurobiology & Anatomy Microscopy Facility, supported, in part, with funding from
NIH-NINDS Center core grant (5P30NS047463)
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CHAPTER 4: PHYSIOLOGICAL CHANGES OF THE ENDOCANNABINOID
SYSTEM FOLLOWING GLUTAMATE INJURY

A. Introduction:
Epilepsy is a common and debilitating neurological condition characterized by
spontaneous recurrent seizures. It affects over 2.7 million people in the United States
(Kobau et al., 2005). Epilepsy can be cryptogenic in nature, in which there is likely a
genetic cause, or it can be an acquired epilepsy (AE) which develops after a precipitating
incident such as traumatic brain injury, CNS infection, status epilepticus or stroke
(DeLorenzo et al., 2005; Elger and Schmidt, 2008). After a brain trauma, a cascade of
events causes many neuronal changes, including transcriptional changes, mossy fiber
sprouting, and neurogenesis (Rakhade and Jensen, 2009) during the period known as
epileptogenesis. These neuronal changes can then lead to the expression of the epileptic
phenotype. The changes that occur during epileptogenesis are important to study to
further advance our knowledge of AE so we may develop novel treatments and therapies
to prevent or better treat this debilitating condition. Among receptor systems that undergo
plasticity changes during epileptogenesis, the endocannabinoid system has come to the
forefront of neuroscience research.
The endocannabinoid system includes the CB1 and CB2 receptors, their
endogenous ligands, N-arachidonyl ethanolamine (anandamide, AEA) (Munro et al.,
1993) and 2-arachidonylglycerol (2-AG) (Mechoulam et al., 1995) and the protein
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machinery to synthesize, reuptake and degrade the endocannabinoids. In the CNS, the
CB1 receptor is the most prevalent G-protein coupled receptor and it is expressed at high
levels in the hippocampus, cortex, cerebellum, and basal ganglia (Herkenham et al.,
1990; Herkenham et al., 1991; Tsou et al., 1998). Endogenous cannabinoids
(endocannabinoids) are synthesized and released on demand from the post-synaptic cell
during periods of high activity. The endocannabinoids then travel retrogradely and bind
to the CB1 receptor on the pre-synaptic cell leading to the suppression of voltage-gated
Ca2+ channels (Alger, 2004; Twitchell et al., 1997). The suppression of presynaptic
Ca2+channels inhibits the release of neurotransmitters from the cell, thereby causing a
transient inhibition in cell signaling. In addition, CB1 receptor activation also inhibits
adenylyl cyclase, causing decreased levels of intracellular cAMP, and stimulation of
potassium channels (A-type and inwardly rectifying), leading to an increased efflux of
potassium (Lutz, 2004). The on-demand synthesis and release of endocannabinoids
during periods of increased neuronal activity and the localization of CB1 receptors at both
inhibitory (Hajos et al., 2000; Katona et al., 1999) and excitatory (Katona et al., 2006;
Kawamura et al., 2006; Marsicano and Lutz, 1999) terminals further point to the
importance of the endocannabinoid system in modulating synaptic transmission in
disease states such as epilepsy (Alger, 2006).
One of the mechanisms that the endocannabinoid system relies on to modulate
neurotransmission is the activity dependent suppression of inhibition or excitation.
Dependent on what class of terminals the CB1 receptor is present, this regulatory
mechanism is termed depolarization-induced suppression of inhibition (DSI- when
GABA is involved) or excitation (DSE- when glutamate is involved). DSI is long known
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to be an endocannabinoid mediated phenomenon that occurs in CA1 and CA3 pyramidal
cells and dentate gyrus granule cells in the hippocampus (Alger, 2002). DSI occurs in the
hippocampus when a brief activation of the post-synaptic cell causes the on-demand
synthesis and release of endocannabinoid 2-AG, which then activates the CB1 receptors
on the pre-synaptic cell (CCK-positive interneurons), briefly inhibiting their release of
GABA. Thus, there is a transient suppression of the inhibitory signal to the post-synaptic
cell.
The glutamatergic terminal equivalent of DSI is the depolarization induced
suppression of excitation (DSE). DSE has been more challenging to study in the
hippocampus compared to cerebellum. Studies have shown that DSE is more difficult to
induce in hippocampal cells and it requires a longer activation of the post-synaptic cell
than what is observed in the cerebellum (Ohno-Shosaku et al., 2002). Reasons for this
apparent discrepancy could be that there may be a greater number of receptors on the
excitatory nerve terminals in the cerebellum, or better access of the released
endocannabinoid to the receptors on the excitatory nerve terminals (Alger, 2002). In
addition, age may also play a role in the ability to induce DSE, as studies have shown that
the CB1 agonist WIN 55,212-2 reduced field EPSPs in tissue from younger animals,
while tissue from older animals failed to show an effect (Al-Hayani and Davies, 2000).
Though the methods of recording were slightly different, DSE has been observed in
tissue from young animals (Ohno-Shosaku et al., 2002), but not in tissue from older
animals (Hajos et al., 2001). In general, DSE in the hippocampus is less robust than DSI,
generally only showing a 30% suppression of EPSCs compared to a 50% or more
suppression of IPSCs in DSI (Alger, 2002; Ohno-Shosaku et al., 2002).
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DSI and DSE are important physiological functions to study in the epileptic state,
as several histological studies have shown a relative upregulation of the CB1 receptor in
animal models of epilepsy(Chen et al., 2003; Monory et al., 2006; Wallace et al., 2003).
However, functional importance of these receptor changes in epilepsy (Chen et al., 2007)
have not been thoroughly explored. It has long been known that cannabinoids have an
anti-convulsant effect in epilepsy. Studies from this laboratory have found that
administration of the CB1 agonist R(+)WIN55,212-2 (WIN) to epileptic animals or cell
cultures reduced their seizure frequency (Blair et al., 2006; Wallace et al., 2003). It has
been postulated that there is a basal endocannabinoid tone that controls excitability in the
epileptic phenotype and prevents the progression to lethal SE. Indeed, our laboratory has
shown that by selectively blocking the CB1 receptors with the CB1 antagonist N(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3carboxamidehydrochloride (SR141716A), the seizure frequency of epileptic animals
increased 5-fold from baseline and some epileptic animals even developed status
epilepticus (Wallace et al., 2003). A similar phenomenon was also observed in the
hippocampal neuronal culture model of AE (Deshpande et al., 2007d). These studies
point to a physiologically important role of the CB1 receptors at the excitatory synapses
in controlling seizure activity. These findings are in agreement with Monory et al
(Monory et al., 2006) who showed that selectively deleting CB1 receptors at
glutamatergic terminals significantly increased their susceptibility to kainic-acid induced
seizures but not when CB1 receptor was absent from the GABAergic terminals. This
again supports the important functional role of CB1 receptors at excitatory synapses in
controlling seizure activity.
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Immunohistochemical studies from our laboratory have confirmed that the
development of epilepsy causes unique changes to the endocannabinoid system. Falenski
et al (Falenski et al., 2007) utilized the pilocarpine model of acquired epilepsy and found
a decrease in CB1 receptor labeling at the pyramidal cell neuropil and dentate gyrus inner
molecular layers of the hippocampus. In addition, a marked increase in CB1 receptor
labeling was noted in the stratum radiatum and oriens, suggesting an increase in CB1
receptors in areas of excitatory synapses with a decrease in CB1 at inhibitory synapses.
CB1 receptor binding and G-protein activation were also studied to confirm a functional
reorganization of the CB1 receptors (Falenski et al., 2007). These anatomical and
pharmacological findings have led us to hypothesize that the relative redistribution of
CB1 receptors act as a compensatory mechanism to assist in controlling seizures in
epileptic animals from transitioning into the more dangerous state of status epilepticus
(SE). This would suggest that the increase in CB1 receptors at the excitatory terminals act
to dampen the excitatory signals between cells and the decrease at inhibitory terminals
would allow for greater inhibition during an excitatory state. However, this hypothesis
has yet to be fully explored at a physiological cellular level.
This study was initiated to explore the hypothesis that there is a physiological
change in cannabinoid modulation of DSI and DSE in epilepsy. Utilizing a novel
organotypic hippocampal slice culture (OHSC) model of stroke induced acquired
epilepsy, we are able to study DSI and DSE in an in vitro system that shares many
characteristics of other in vivo and in vitro models of acquired epilepsy (chapter 2) and
also displays an upregulation of CB1 receptors (chapter 3). The results from this study
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provide functional physiological evidence that the CB1 receptor upregulation may in fact
play a compensatory role in the epileptic state.

B. Methods:
Organotypic hippocampal slice culture preparation
Slice cultures were prepared using the method of Stoppini et al. (Stoppini et al.,
1991), as previously reported by (Schanuel et al., 2008). All animal use protocols are in
strict accordance with the National Institute of Health guidelines for the Care and Use of
Laboratory Animals and are approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University. Postnatal day 8 (P8) Sprague-Dawley
rat pups (Harlan, Frederick, MD, USA) were deeply anesthetized with isoflurane and
decapitated. The brains were removed, and hippocampi were dissected and cut into 350µm transverse sections using a McIlwain tissue chopper (Brinkmann Instruments,
Canada) and placed into Hank’s balanced salt solution [HBSS – Gibco BRL (Invitrogen,
Carlsbad, CA, USA)] supplemented with 0.5% sucrose and 1% penicillin-streptomycin.
The middle four to six slices of each hippocampus, including part of the entorhinal
cortex, were placed onto tissue culture membrane inserts (Millipore, Bedford, MA) in a
6-well tissue culture dish containing maintenance medium composed of 50% minimum
essential medium, 25% horse serum and 25% HBSS, 1% penicillin-streptomycin [all
from Gibco BRL (Invitrogen, Carlsbad, CA)] and supplemented with 36 mM glucose,
and 25 mM Hepes (Sigma, St. Louis, MO, USA) (pH 7.2). Cultures were maintained at
34°C under room air +5% CO2. After 1 day in culture, culture medium was replaced with
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fresh maintenance medium containing no antibiotics. Culture medium was replaced two
times a week thereafter.

Glutamate injury protocol
After 21 days in vitro (DIV21), slice culture media was replaced by media
containing 3.5mM glutamate for a period of 35 minutes (Lipski et al., 2007). At the end
of this period, glutamate containing media was removed and slice cultures were washed
with HBSS at 34°C two times before returning to normal media. Control slices received
normal media (without glutamate) during the 35 minute time period, followed by
washing with HBSS twice before returning to normal media.

Intracellular recording from OHSCs
At DIV 28-33 OHSCs were excised from culture inserts and transferred to a
recording chamber mounted on an upright microscope (Axioskop2, Zeiss, Germany)
equipped with IR/DIC optics. Slices were perfused with aCSF (composed of: in mM)120
NaCl, 3.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1.25 NaH2PO4, 25.6 NaHCO3, and 10 glucose,
equilibrated with 95% O2-5% CO2) at a rate of 1-2 ml/min at room temperature (25oC)
with a peristaltic pump (Rainin Instruments, Oakland CA). aCSF was supplemented with
bicuculline (10 µM) for recording EPSCs and with CNQX (10 µM) and APV (50 µM)
for recording IPSCs (Ohno-Shosaku et al., 2002). Patch electrodes with a resistance of 2
to 4 MΩ were pulled on a Brown-Flaming P-80C electrode puller (Sutter Instruments,
Novato, CA). For sIPSC recordings, pipettes were filled with cesium based intracellular
solution containing (in mM): 100 CsCH3SO3, 40 CsCl, 3 KCl, 0.2 EGTA, 0.02 CaCl2, 1
MgCl2, 2 ATP, 0.3 GTP, 10 HEPES, and 5 QX-314 (lidocaine N-ethyl bromide), pH
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balanced to 7.2 with CsOH, osmolarity adjusted to 290 with sucrose. For sEPSC
recordings, pipettes were filled with a potassium gluconate based solution containing (in
mM): 120 K-gluconate, 15 KCl, 6 MgCl2, 0.2 EGTA, 10 HEPES, 5 NaATP, and 5 QX314, pH balanced to 7.3 with KOH, osmolarity adjusted to 290 with sucrose. QX-314 is a
local anesthetic that is membrane impermeable. By adding QX-314 to the pipette
solution, voltage-gated Na+ conductances and regenerative spiking activity are blocked,
leaving only Ca2+ conductances.(Pitler and Alger, 1994). CA3 pyramidal cells were
morphologically identified at 63X magnification and electrodes were manipulated to
visually patch the cell with hydraulic micromanipulators. Cells were accepted for
evaluation if series resistance was stable within 15% during experimentation. Whole cell
voltage clamp recordings were obtained from one cell per slice. Recording protocol
included holding cells at –60mV for 90 seconds, followed by a 5 second voltage step to
0mV for DSI, 10 second voltage step for DSE. This protocol was repeated 1-5 times for
each cell.

Recording of evoked currents
Composition of pipette and extracellular solutions were similar to the solutions
used for spontaneous recordings (see above). A bipolar stimulation electrode (FHC Inc,
Bowdoin, ME) constructed from Teflonplaced in the stratum radiatum of the CA3 area to generate eEPSCs or eIPSCs. The
placement and distance of the recording and stimulating electrodes was kept constant. To
evoke currents, a minimal stimulation pulse (5stimulating electrode at a rate of 0.33Hz. The depolarizing pulse used to evoke DSI and
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DSE was a 5s or 10s step to 0 mV from a holding potential of –60 mV delivered through
the recording electrode, respectively.

Delivery of CB1 receptor antagonist
To investigate whether the DSI and DSE phenomena were CB1 dependent, we
utilized the CB1 receptor antagonist N-(piperidin-1-yl)-5- (4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A).
SR141716A was dissolved in DMSO. The final concentration of DMSO in the bath
solution was 0.02%. OHSCs were pre-

Data analyses
Recordings were low-pass filtered at 2 kHz, sampled at 10 kHz and stored using
the Pclamp software (version 10, Molecular Devices, Sunnyvale, CA) employing analogdigital interface Digidata 1440A (Molecular Devices). Off-line analysis of data was
performed using Clampex software (version 10.2, Molecular Devices). For DSI and DSE
measurements, the magnitudes of suppression are expressed as percent decrease in sIPSC
or sEPSC charge transfer after the depolarizing pulse with respect to pre-pulse control
period respectively. Student’s t-test was utilized for analyzing the DSI/ DSE data by
comparing charge transfer before and after the depolarization (Martin et al., 2001). To
evaluate the event frequency of spontaneous events, we evaluated the number of IPSPs or
EPSPs that occurred 30 seconds before the depolarization and 20 seconds after, excluding
the first 2 seconds after depolarization to allow for maximal DSI (Alger et al., 1996). To
evaluate DSI and DSE in spontaneous recordings, these periods were evaluated as charge
140

transfer for each 5 second period such that each 5 second period was calculated as [%
charge of pre-depolarization = average charge transfer per period (pA/s) / average charge
transfer (pA/s) during pre-depolarization period]. For evoked currents, the amplitude of
the 8 events preceding depolarization were compared to the 3 events following (Zhang
and Alger, 2010). To examine suppression of inhibition or excitation, the data is
represented as [% amplitude of pre-depolarization = average amplitude of 3 events after
depolarization / average amplitude of 8 events before depolarization]. Statistical tests
were performed using SigmaStat 2.0 and graphs were generated using SigmaPlot 11
(Systat Software Inc., San Jose, CA). All data is represented as mean ± SEM. N refers to
number of OHSCs. Unless otherwise noted, Student’s t-test was used to evaluate
significance. A value of p< 0.05 is considered statistically significant.

C. Results
Increased excitability and decreased inhibition in glutamate treated slices
There were significant differences in IPSC and EPSC frequency between control
and glutamate treated OHSCs. Control OHSCs showed a higher IPSC frequency and a
lower EPSC frequency than the glutamate treated slices. During recording of IPSCs,
control slices showed an event frequency of 2.89 ± 0.67 Hz (n=14), while glutamate
treated OHSCs had a spontaneous IPSC frequency of 0.69 ± 0.12 Hz (n=6, p=0.048). In
addition, the amplitude of IPSCs observed in control OHSCs (-94.03 ± 2.56 pA, n=1244
events) was significantly larger than those in glutamate treated slices (-16.56 ± 0.41 pA,
n=93 events, p<0.001). In contrast, during EPSC recording, control OHSCs had a
spontaneous event frequency of 0.88 ± 0.15 Hz (n=7), compared to glutamate treated
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OHSCs that displayed a spontaneous event frequency of 2.33 ± 0.41 Hz (n=8, p=0.007).
The amplitude of EPSCs in glutamate treated slices (-74.19 ± 1.70 pA, n=748 events)
was also significantly larger than those observed in controls (-35.93 ± 0.774 pA, n=158
events, p<0.001). This indicates a significant increase in excitatory tone in glutamate
treated OHSCs, with a decrease in inhibitory tone.

DSI is similar in control and glutamate treated OHSCs during spontaneous recording
To measure DSI we measured events for 30 s before depolarization and 20s after
and then expressed DSI as change in charge transfer. Representative traces are displayed
in Figure 22. During spontaneous recordings of IPSCs, both control (n=16) and
glutamate (n=9) treated OHSCs displayed a significant suppression in charge transfer
after depolarization of the CA3 pyramidal cell. Control OHSCs displayed a significant
(p< 0.05) decrease in charge transfer from the pre-depolarization period at the 5 second
(36.9 ± 8.7%), 15 second (66.0 ± 12.4%), and 20 second (64.0 ± 10.0%) time points. The
10 second (60.1 ± 18.3%) time point was not significantly different from the predepolarization charge transfer. Glutamate treated slices showed a significant depression
in sIPSC charge transfer at 5 (18.7 ± 6.1%), 10 (31.9 ± 10.5%), and 15 seconds (46.8 ±
15.2%), but sIPSC charge transfer was not significantly different from pre-depolarization
by 20 seconds (74.7 ± 10.2%) (Figure 23). There were no significant differences in the
amount of depression between the two groups at any of the time points suggesting that
glutamate injury does not play a significant role in DSI expression.
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DSE is increased in glutamate treated OHSCs
DSE in spontaneous recordings was measured as the difference in charge transfer
of spontaneous EPSCs before depolarization and after depolarization. Representative
traces are displayed in Figure 24. Change was expressed as a percent of the average predepolarization charge transfer. When testing for DSE in control we found no significant
suppression of excitation following post-synaptic cell depolarization (n=13). Normalized
to pre-stimulation values, control OHSCs displayed an average sEPSC charge transfer of
87.8 ± 9.5% at 5 seconds, 92.1± 9.3% at 10 seconds, 122.6 ± 11.2% at 15 seconds, and
114.5 ± 13% at the 20 second time point. On the other hand, glutamate treated slices
(n=12) showed significant (p< 0.05) suppression of sEPSCs after depolarization at both
the 5 second (50.8 ± 8.5%) and 10 second (64.5 ± 12.0%) time points, but this
suppression was no longer significant at 15 (73.6 ± 9.7%) or 20 (78.6 ± 8.7%) seconds
after depolarization. These values were significantly different from control values at 5,
15, and 20 seconds as displayed in Figure 25.

DSI and DSE are CB1 mediated
Employing a stimulating electrode to evoke EPSCs and IPSCs allowed us to
further evaluate DSI and DSE in our OHSC model. Interestingly, we did not observe as
much DSI in evoked potentials as we did in our spontaneous IPSC recordings.
Representative traces are displayed in Figure 26. In control OHSCs, the average postdepolarization eIPSC amplitude was 78.1 ± 4.55% (n=10) of the pre-depolarization
amplitude. In glutamate treated slices, we saw even less DSI, with a post-depolarization
amplitude of 94 ± 3.7% (n=8) of the pre-depolarization eIPSC amplitude. These two
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values are significantly different from one another, indicating a greater amount of DSI in
control OHSCs than those that had undergone glutamate treatment (p=0.019, Student’s ttest). The addition of SR141716A to the culture media and perfusion solution also
revealed that the DSI observed in control OHSCs is in fact CB1 mediated. DSI was not
observed in cultures that had SR141716A present in the recording solution. The average
control eIPSC pre-depolarization amplitude was 106.6 ± 5.4% (n=4) of the predepolarization amplitude, indicating that DSI did not occur. This was significantly
different from the control value that did not receive SR141716A treatment (p=0.004, ttest). Glutamate treated OHSCs that were exposed to SR141716A also did not show DSI,
with a post-depolarization amplitude equal to 104.3 ± 2.3% (n=5) of the predepolarization amplitude. However, this is not statistically significant from the small DSI
observed in glutamate treated OHSCs that did not undergo SR141716A treatment
(p=0.071, Figure 27).
When observing DSE in evoked potentials, our results are similar to those
observed in spontaneous EPSCs. Control OHSCs did not display DSE, with a postdepolarization amplitude of 101.1 ± 12.6% (n=5) of the pre-depolarization amplitude.
This is significantly different from the DSE observed in glutamate treated OHSCs
(p=0.050). Glutamate treated OHSCs display an average post-depolarization amplitude of
61.6 ± 11.9% (n=6) of the pre-depolarization amplitude, indicating a significant amount
of DSE. Addition of SR141716A to the culture media and perfusion solution block this
DSE, indicating that it is a CB1 mediated effect. In control OHSCs, the addition of
SR141716A lead to an amplitude of 98.1 ± 3.3% (n=4) of pre-depolarization, indicating
no DSE had occurred. In glutamate treated OHSCs a 107.8 ± 10.1% (n=4) amplitude of
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pre-depolarization was observed, also indicating that SR141716A had blocked DSE. This
observation was significantly different from glutamate treated slices that were not
exposed to SR141716A (p=0.026), while control slices displayed no significant change
(p=0.842) (Figure 28).
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Figure 22- Changes in DSI following stroke-like injury in OHSCs.
Current traces from CA3 pyramidal cells from age-matched control (A) and from a
OHSC displaying following glutamate injury (B). The recordings were carried out in the
presence of ionotropic glutamate receptor antagonists for IPSC measurements. The
sIPSCs appeared depressed shortly after a depolarizing voltage step (5 s to 0 mV from 70 mV), indicated by the square pulse above the trace, representing DSI. Note that DSI
was more prominent and easier to evoke in controls.
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Figure 23 – Time course of DSI.
DSI was observed in both control (closed circle) and glutamate treated (open
triangles) OHSCs. There was no significant difference between the two groups at any
time point. Significant (P<0.05) DSI is observed from the -5 sec time point in both
control (#) and glutamate treated (*) samples.
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Figure 24. Changes in DSE following stroke-like injury in OHSCs.
Current traces from CA3 pyramidal cells from age-matched control (A) and from a slice
culture displaying following glutamate injury (B). The recordings were carried out in the
presence of GABAA receptor antagonists for EPSC measurements. The sEPSCs appeared
depressed shortly after a depolarizing voltage step (10 s to 0 mV from -70 mV), indicated
by the square pulse above the trace, representing DSE. Note that DSE was more
prominent and easier to evoke in glutamate treated OHSCs than controls.
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Figure 25– Time course of DSE
DSE was observed in the glutamate treated OHSCs, but not in the controls. There was
a significant depression of EPSCs in glutamate slices (*) after the depolarizing pulse.
This was significantly different from what was observed in controls ($). There was no
significant depression in EPSCs in control OHSCs.
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Figure 26 – Traces of evoked currents
IPSCs (a) and EPSCs (b) were evoked by placing a stimulating electrode in the stratum
radiatum of the CA3 region while recording from a CA3 pyramidal cell. Currents were
evoked at a rate of 0.33 Hz and a 5 sec (DSI) or 10 sec (DSE) depolarizing voltage step
was applied to the pyramidal cell every 90 seconds. To measure DSI or DSE, we
averaged the amplitude of the 8 evoked currents before the depolarization and compared
them to the 3 currents following depolarization to calculate the suppression observed.
Evoked current suppression was more apparent in controls while measuring DSI and in
glutamate treated OHSCs when measuring DSE.
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Figure 27 - eIPSCs reveal DSI in control OHSCs is CB1 mediated.
By stimulating the slice to observe evoked IPSCs, we only observed DSI in control
OHSCs. This was significantly different from what was observed in glutamate treated
OHSCs. We also observed a significant difference in IPSC amplitude after control
OHSCs had been treated with the CB1 receptor antagonist SR141716A (SR). This
suggests that the DSI observed in control OHSCs is CB1 mediated.
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Figure 28 - eEPSCs reveal DSE in glutamate treated OHSCs is CB1 mediated.
Recording of evoked excitatory currents revealed significant DSE in glutamate treated
OHSCs, but not in controls, similar to what was observed in spontaneous recordings.
Addition of SR141716A (SR) to the recording media also suggested that this
phenomenon was CB1 mediated.
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D. Discussion:
These studies were performed to investigate functional significance of
cannabinoid receptor upregulation and redistribution in epilepsy. We first measured basal
excitability in control and epileptic state. The results demonstrate that there is decreased
inhibition and enhanced excitation in epileptic OHSCs compared to control OHSCs
indicating increased excitability in epileptic condition. DSI and DSE were then measured
to understand changes in activity dependent plasticity of endocannabinoid signaling.
While no significant changes in DSI were observed, a significant increase in DSE was
observed in epileptic OHSCs compared to control OHSCs. This suggests that following
epilepsy, the CB1 receptor redistribution on glutamatergic terminals is acting to inhibit
glutamate release thereby preventing persistent excitability and its transformation into a
state of SE.
These results evaluated the physiological significance of the CB1 receptor
upregulation we observed in chapter 3. In this approach we are able to further examine
DSI and DSE and overall excitatory and inhibitory tone after glutamate injury. Our
observation that there is relatively little DSE observed in control slices compared to
glutamate injured slices is in agreement with our hypothesis that CB1 upregulation in
acquired epilepsy is a compensatory mechanism for controlling seizure activity.
However, we were somewhat surprised by the conflicting results we observed while
recording DSI from both spontaneous and evoked IPSCs. Our immunohistochemical data
from chapter 3 showed a significant increases in CB1 receptor staining in the stratum
oriens of the CA1 region and stratum radiatum of the CA3 region (where the
glutamatergic synapses are located), with no significant changes in the pyramidal cell
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regions (where the GABAergic synapses are located). The physiological data obtained in
our spontaneous recordings supports the notion that these CB1 receptor changes are
functional. An increase in DSE with no change in DSI in glutamate treated slices also
supports our hypothesis that the relative upregulation of CB1 receptors after glutamate
injury acts to suppress seizure activity.
However, we observed slightly different results in DSI recording with evoked
currents where glutamate treated slices did not display significant DSI and controls slices
saw post-depolarization amplitude of 83% of the pre-depolarization amplitude. Both
control and glutamate treated OHSCs displayed a much greater depression of sIPSCs
when recording spontaneous activity to 37% and 19% of pre-depolarization values,
respectively. These discrepancies, however, may be inherent to the different modes of
recording and reporting. In glutamate treated OHSCs, there was generally less sIPSC
activity than in controls. This lack of activity may skew our spontaneous data to show a
greater suppression when in fact there was just less activity overall. The DSI observed in
our evoked potentials for both control and glutamate treated slices is far less than what is
observed in other hippocampal studies that often observe a 50% suppression of inhibition
(Alger et al., 1996; Alger, 2002; Lenz and Alger, 1999). This may indicate a diminished
role of the endocannabinoid system on overall GABAergic signaling in our OHSCs. It
may also be that our depolarizing voltage step was too long to induce maximal DSI, as
recent studies have shown greater DSI with a 250 ms step than with a 2 s step (Isokawa
and Alger, 2006). A longer depolarization may shift more endocannabinoid signaling to
the excitatory pathways. This phenomenon will require further future investigation.
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It has also been noted that DSI may not be the important CB1 mediated
physiological function in the control of epilepsy. Selective deletion of CB1 receptors on
GABAergic terminals failed to change susceptibility to kainic acid seizures (Monory et
al., 2006). In our model, it may be that DSE is the more important cannabinoid mediated
effect in acquired epilepsy. In a normal hippocampus, DSE requires a longer
depolarization than what may be physiologically relevant in normal tissue. However,
with the prolonged depolarization that may occur in epilepsy, DSE may play a very
active role in controlling seizures. Our results in both spontaneous and evoked EPSCs
point to greater control of CB1 receptor activation in inhibiting excitatory transmission in
a chronic epileptic state. Thus, the increase in CB1 receptor expression after the
development of epilepsy plays a functional role in neuroprotection in this model. It has
been shown that inducing DSE in hippocampal tissue is dependent on the sensitivity of
the presynaptic neuron to cannabinoids as well at the duration of postsynaptic
depolarization (Ohno-Shosaku et al., 2002). With extended depolarization, the result of
CB1 receptor activation may be a shift from DSI to DSE. Therefore, the extended
neuronal depolarization of an epileptiform discharge may cause a greater suppression of
glutamate release rather than a suppression of GABA release (Wallace et al., 2003).
Of course, this is not necessarily the role of the endocannabinoid system in all
epilepsies. Chen et al (Chen et al., 2007) have studied the CB1 receptor in a hyperthermia
model of febrile seizures. They induced febrile seizures in neonatal P3 rats and found and
overall increase in CB1 receptor expression in their brains at P10. However, paired
neuron recordings revealed an increase in DSI in hyperthermia animals with no change in
DSE between hyperthermia and control animals. This is in contradiction to observations
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from our study. However, age may play an important role in functional CB1 receptor
plasticity. Our study injured the tissue that had been cultured for 21 days from P8 rats, so
it was roughly equivalent to neurons from a 4 week old rat (Caeser and Aertsen, 1991;
Finley et al., 2004; Thompson et al., 2006). Interestingly, in addition to cannabinoid
sensitivity, age of the animal may be an important factor in inducing DSE in healthy
tissue. Several studies have shown that cannabinoids induce suppression of EPSCs occurs
in young (Al-Hayani and Davies, 2000; Ameri and Simmet, 2000) or tissue cultured
tissue (Sullivan, 1999), but show no effect on EPSCs in adult tissue (Stella et al., 1997).
This discrepancy in developmental stage at the time of injury could play a role in
differential plasticity of the CB1 receptors after injury. This may also help explain why
we do not observe DSE in control tissue. The relatively small number of CB1 receptors
present at glutamatergic synapses in control tissue may not respond readily enough to
display DSE in our model, whereas the upregulation of CB1 after injury causes enough
activation to display DSE as in a more juvenile state.
This study provides some important insight into the functional relationship of CB1
receptor expression and physiological activity following the development of acquired
epilepsy. Future studies of this kind are necessary in other in vitro and in vivo models to
truly understand the role of the endocannabinoid system in regulating seizure activity, as
they could have great clinical implications in specifically targeting receptors that control
seizures.
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GENERAL DISCUSSION

A. Rationale and summary of the central hypothesis
Seizure activity and epilepsy have been studied extensively in various
experimental animal models using chemoconvulsants like NMDA, kainic acid,
metabotropic glutamate receptor agonists and antagonists, GABA receptor antagonists or
blockers (e.g. bicuculline, picrotoxin, pentylenetetrazole) and cholinergic agonists (e.g.
pilocarpine), electrolytic hilar lesions or kindling, (reviewed by (Fisher, 1989)). All
treatments elicit varying degrees of hippocampal cell death ranging from limited to
extensive neuronal degeneration. In addition, these animal models display hippocampal
structural changes with increased dentate granule cell neurogenesis (reviewed in (Parent,
2007)) and recent studies from our laboratory have also noted a significant reorganization
in the cannabinoid CB1 receptor expression in the hippocampus (Falenski et al., 2007;
Falenski et al., 2009). Since the detailed mechanisms involved in these changes are far
from known, a simplified, yet organotypic in vitro model for seizure activity would be
helpful. The experiments performed in this dissertation have sought to establish and
evaluate a new model of stroke-acquired epilepsy in organotypic hippocampal slice
cultures.
Cerebral ischemia is a catastrophic event with significant morbidity and mortality.
It is the leading cause of acquired epilepsy in persons 35 and older (Forsgren et al.,
1996)with patients who have suffered a cerebral infarct having a 17-fold greater risk of
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developing recurrent seizures (Warlow et al., 2003), yet little is known about the
underlying basic mechanisms leading to stroke induced epilepsy. Our laboratory has
previously utilized a hippocampal neuronal culture (HNC) model of stroke acquired
epilepsy to study some of the molecular changes that occur in Ca2+ regulation in neurons
following a stroke-like injury (Sun et al., 2001; Sun et al., 2004). Models of stroke
induced epilepsy have been difficult to develop in vivo, but organotypic hippocampal
slice cultures (OHSCs) provide and ideal substrate for developing an in vitro model of
stroke induced AE while maintaining normal cellular connections. OHSCs have been
utilized for years in various studies of stroke and seizures, though the physiological
effects of a stroke-like injury have not been fully explored in this system. Slice cultures
have a distinct advantage over the HNC model in that they maintain normal cellular
morphology and architecture (Bahr, 1995), while allowing for easy manipulation. OHSCs
have been studied extensively in oxygen-glucose deprivation and glutamate injuries to
mimic the effects of ischemia. Most studies have focused on manipulating the system to
prevent cell death (Lipski et al., 2007; Noraberg et al., 2005), without looking at the long
term physiological outcomes. In addition, few studies have utilized OHSCs to produce
spontaneous recurrent seizures as a model of acquired epilepsy (Bausch et al., 2006;
Routbort et al., 1999). With this in mind, this dissertation has focused on developing a
model of stroke-like injury in OHSCs to study the physiological and molecular
consequences following injury.
Extensive research in animal models (Araujo et al., 2010; Deshpande et al.,
2007b; Wallace et al., 2003) along with human studies (Ludanyi et al., 2008) suggest that
modulation of the endocannabinoid system plays a role in epilepsy. Our laboratory has
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studied the endocannabinoid system in the rat pilocarpine model of epilepsy in great
depth. Studies have found that there is a unique, functional redistribution of CB1
receptors in the hippocampus during the development of epilepsy (Falenski et al., 2007;
Wallace et al., 2003), with an overall increase in CB1 receptor expression. The
redistribution shown supports the hypothesis that the changes in CB1 expression act as a
compensatory mechanism to control seizures. Research also shows that the
endocannabinoid system undergoes modulation in cerebral ischemia (Hillard, 2008). A
model of stroke induced acquired epilepsy provides an ideal system for studying the
endocannabinoid system following stroke-like injury and during epileptogenesis. OHSCs
express CB1 receptors similarly to in vivo tissue (Boscia et al., 2008), indicating that
OHSCs are an appropriate system to study CB1 receptor changes. Based on in vitro and in
vivo research in the literature and preliminary electrophysiology studies, we developed
two central hypotheses for this dissertation. We hypothesized that status epilepticus and
stroke like injuries cause increased neuronal excitability in organotypic hippocampal slice
cultures, rendering a model of acquired epilepsy. In addition, we hypothesized that the
endocannabinoid system plays a modulatory role in stroke-induced acquired epilepsy in
our OHSC model. Addressing the following experimental questions in this dissertation
has thoroughly tested our hypotheses.
1. Does a status epilepticus like injury induce spontaneous recurrent
epileptiform discharges in our organotypic hippocampal slice cultures?
2. Does a stroke-like injury induce spontaneous recurrent epileptiform
discharges in organotypic hippocampal slice cultures?
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3. Are CB1 receptors upregulated in OHSCs following glutamate injury?
What is the distribution of the CB1 receptors that display seizure activity?
4. Is there a functional difference in CB1 receptor activity following a strokelike injury?

B. 4-aminopyridine exposure causes spontaneous seizure activity in OHSCs.
We have successfully cultured and maintained viable organotypic hippocampal
slice cultures in our laboratory. In the first part of this thesis, we established that OHSCs
in our hands would acutely respond to the K+ channel blocker 4-aminopyridine (4-AP) as
previously shown in the literature (Albus et al., 2008). We confirmed that 4-AP acutely
caused prolonged electrographic seizures and was therefore suitable to use for a status
epilepticus (SE) like injury. We therefore utilized 4-AP to induce a longer, status
epilepticus like injury by including 200µM 4-AP to culture media for a 24 hour period.
This led to a significant amount of cell death acutely following the injury period, but cell
death was not significantly different from controls in the time periods after the injury
period (5 and 14 days). The pattern of cell death appeared to mostly occur in the
glutamatergic cells in the pyramidal cell and dentate granule cell layers. This follows the
pattern of cell death observed in animal models of SE (Poirier et al., 2000). Our findings
also agree with the temporal aspect of cell death seen in other models of acquired
epilepsy, wherein there is significant cell loss immediately following the injury, but not
during the period of epileptogenesis (Deshpande et al., 2007c; Raza et al., 2004).
Following prolonged treatment with 4-AP, we observed a significant increase in
spontaneous seizure activity in OHSCs that underwent 4-AP treatment, with 62% of
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cultures displaying seizure activity in the CA3 region. This was significantly increased
from our control slices, indicating that 24 hour treatment with 4-AP lead to an increase in
spontaneous seizures 14 days later in slice cultures.
The development of this model of SE induced acquired epilepsy provides insights
into the maintenance and handling of OHSCs. Our spontaneous seizure rate in this study
was significantly higher than what has been reported in OHSCs treated with kainic acid
in which 29% of OHSCs displayed seizures in the DG region (Bausch and McNamara,
2004), but it was not as significant as what has been observed in OHSCs treated with
TTX (Bausch et al., 2006) in which 89% of OHSCs displayed seizure activity following
removal of chronic blockade of activity. These three different injury mechanisms provide
some insight into the receptor systems that may be involved in epileptogenesis. Kainic
acid acts on the kainate receptors, which play a significant role in modulating synaptic
plasticity in the hippocampus (Contractor et al., 2000). Prolonged agonism of this
receptor did not cause the plasticity changes that resulted in a significant rate of seizures
in OHSCs (Bausch and McNamara, 2004). 4-AP blocks K+ channels and though it does
not act directly on NMDA receptors, 4-AP induced convulsive activity in vivo involves
NMDA receptors, since 4-AP exposure leads to excessive release of glutamate (FragosoVeloz and Tapia, 1992). In our model, prolonged treatment with 4-AP induced
epileptogenesis. In the final example, chronic treatment of OHSCs with TTX induces
plasticity of both excitatory and inhibitory synapses. Upon removal of the blockade of
action potentials, the impact of these synaptic plasticities results in spontaneous seizures
(Bausch et al., 2006). Of these mechanisms, the exposure to excessive glutamate may
play a physiological role in many injuries known to induce epileptogenesis including
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status epilepticus and stroke.
Excessive release of glutamate is a hallmark of ischemic injury. Activation of
NMDA receptors by excessive glutamate would cause an increase in intracellular Ca2+,
leading to activation of Ca2+ dependent cascades that may induce cell death or the
plasticity changes of epileptogenesis. The potential role of glutamate in our OHSC model
of SE acquired epilepsy requires further exploration and allows for the possibility of a
stroke-like injury model of acquired epilepsy.

C. Stroke-like injury causes acquired epilepsy in OHSCs
The second set of experiments in this dissertation document a new model of
epileptogenesis in OHSCs following glutamate injury. Similar to the excitotoxic injuries
associated with both ischemic and anoxic stroke events, glutamate injury in this model
produced a mixed population of neurons characterized by both cell survival and cell
death. The pattern of cell death after glutamate injury revealed that the CA1 region was
most sensitive to glutamate toxicity. This is similar to what is observed in OHSCs
exposed to NMDA (Kristensen et al., 2001). As in our previous excitotoxic injury in
chapter 1, neurons that survived the glutamate exposure become the substrate for the
development of epileptogenesis as indicated by increased excitability of the CA3 cell
layer in a significant number of OHSCs. The seizure events seen in extracellular
recordings expressed many characteristics of overt electrographic epileptic seizures and
they responded to the anticonvulsant drugs phenobarbital and phenytoin, but not to
ethosuximide. Intracellular recordings confirmed neuronal hyperexcitability in CA3
pyramidal neurons in glutamate treated OHSCs. These results demonstrated that OHSCs
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subjected to injury by glutamate exposure could be transformed into neuronal networks
manifesting seizures for the life of the culture, producing an in vitro model of epilepsy.
Organotypic hippocampal slice cultures have been utilized in many models of
excitotoxicity, including kainic acid (Routbort et al., 1999), NMDA (Ring et al., 2010),
and oxygen glucose deprivation injuries (Lipski et al., 2007). These studies have
generally examined neuroprotective agents during or after an excitotoxic injury, without
looking at the long term physiological consequences (Boscia et al., 2006; Cho et al.,
2007; Lipski et al., 2007; Ring et al., 2010; Routbort et al., 1999; Thomas et al., 2005).
Our model takes this a step further by characterizing the physiological changes after an
excitotoxic injury with glutamate. Our model utilizes glutamate as a mode of
excitotoxicity, as excessive glutamate concentration is an important aspect of the
ischemic penumbra in stroke (Davalos et al., 1997). Previous in vitro studies with a HNC
model used a glutamate-induced prolonged, reversible depolarization as used in this study
(Sun et al., 2001; Sun et al., 2004). Other models of epilepsy have implicated activation
of the N-methyl-D-aspartate receptor (NMDAR) for epileptogenesis (Croucher et al.,
1988; Croucher and Bradford, 1990; DeLorenzo et al., 1998; Rice and DeLorenzo, 1998;
Stasheff et al., 1989). Although the mechanism producing hyperexcitability in this model
has not been fully delineated, it has been shown that inhibition of glutamate receptors in
neurons in culture produces alterations in NMDAR subunit expression that are regulated
by synaptic activity during development (Hoffmann et al., 2000; Yashiro and Philpot,
2008). It is possible that alterations in NMDAR subunit expression may underlie the
development of hyperexcitability in this model after over activation of glutamate
receptors. Though glutamate exposure may induce changes in receptor subunit expression
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in the glutamate injury–induced epileptogenesis model, these potential changes probably
occur through a separate mechanism. Further studies will delineate the receptor changes
that may occur in our model.
Our model also found that there was no difference in the degree of cell death and
the development of seizures. The role of cell death and the development of epilepsy
requires further study as greater cell death in the excitatory neurons should lead to greater
inhibitory tone (Tecoma and Choi, 1989). Further studies are needed to determine the role
of selective cell death in this model and the possible roles of gap junctions, (Dudek et al.,
1998) ischemia-induced alterations in second-messenger systems, and gene changes
(Morris et al., 2000a) in mediating epileptogenesis in this model. In addition, the possible
compensatory mechanisms that control hyperexcitability after an injury is another
important aspect of this model that deserves further attention.

D. CB1 receptors are upregulated after glutamate injury
Chapter 3 of this dissertation demonstrated that the CB1 receptor undergoes
changes in expression in the OHSC model of stroke acquired epilepsy. Western blot
analysis found that CB1 receptor expression rises to 128% of control levels following
treatment with glutamate. This result supports our hypothesis that CB1 receptor
expression changes following an epileptogenic injury and our OHSC model has many
similarities to the molecular changes observed in in vivo models of AE. Densitometric
analysis of immunohistochemical staining of OHSCs further supported our hypothesis the
the CB1 receptor changes play a compensatory role in controlling hyperexcitability, as
observed in the rat pilocarpine model (Falenski et al., 2007; Falenski et al., 2009).
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OHSCs that displayed electrographic seizures showed a specific increase in CB1 receptor
staining in the stratum oriens of the CA1 and stratum radiatum of the CA3 region. This
finding supports the hypothesis that the CB1 receptor upregulation observed in Western
blot analysis is specifically located at the glutamatergic terminals. CB1 receptor
distribution in OHSCs under normal conditions has been shown to be similar to what is
observed in normal rats (Boscia et al., 2008). Specifically, previous studies agree with
images of our control OHSCs, showing the entire hippocampal slice culture decorated
with a dense plexus of CB1-immunoreactive fibers that surrounded the immunonegative
principal cells, mostly located at the GABAergic terminals. The displayed upregulation
further supports the hypothesis that the CB1 receptor changes are a compensatory
mechanism to control seizures. An upregulation at the glutamatergic terminals located in
the stratum radiatum and stratum oriens would play a role in dampening excessive
neuronal excitation.

Several studies of epilepsy have examined the importance of CB1 receptors in
controlling neuronal excitability (Araujo et al., 2010; Arida et al., 2005; Chen et al.,
2003; de Amorim Carvalho et al., 2003; Ludanyi et al., 2008; Monory et al., 2006).
These studies provide an interesting view of the role of the endocannabinoid system in
epilepsy. They suggest that the upregulation of CB1 receptors in animal models of AE
might actually be a compensatory mechanism to control seizure severity after a seizure
precipitating event. The studies of human tissue suggest that this compensatory
mechanism does not develop in humans with intractable epilepsy. Though morphological
studies can strongly support the role of CB1 receptor expression, functional studies are
necessary to confirm that the upregulated receptors are indeed physiologically functional.
172

In vivo studies have utilized [35S] GTP S autoradiography (Falenski et al., 2007),
conditional CB1 gene deletion at glutamatergic terminals (Monory et al., 2006), and the
use of CB1 antagonists (Wallace et al., 2003) to assess the functionality of the CB1
receptor reorganization following the development of epilepsy. These studies further
supported the functional redistribution of the CB1 receptors following epileptogenesis.
Our OHSC model of stroke acquired epilepsy provides an additional advantage in the
ability to readily assess the functionality of the observed receptor upregulation utilizing
electrophysiological techniques. Functional electrophysiology experiments performed in
the final chapter of this dissertation elucidate the physiological changes associated with
an overall increase in CB1 receptor expression after epileptogenic injury.

E. The CB1 receptor upregulation has functional consequences on OHSC excitatory
and inhibitory tone
The final studies of this dissertation were performed to investigate functional
significance of cannabinoid receptor upregulation in epilepsy. By measuring basal
excitability in control and glutamate treated OHSCs, we demonstrated that there is
decreased inhibition and enhanced excitation in glutamate treated OHSCs compared to
controls, indicating increased excitability in the epileptic condition. Depolarization
induced suppression of inhibition (DSI) and excitation (DSE) were then measured to
understand changes in activity dependent plasticity of endocannabinoid signaling. While
no significant changes in DSI were observed, a significant increase in DSE was observed
in glutamate treated OHSCs compared to controls. This suggests that following
epileptogenesis, the CB1 receptor redistribution on glutamatergic terminals is acting to
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inhibit glutamate release thereby preventing persistent excitability and its transformation
into a state of status epilepticus.
These results evaluated the physiological significance of the CB1 receptor
upregulation we observed in chapter 3. The physiological data obtained in our
spontaneous recordings supports the hypothesis that these CB1 receptor changes are
functional. An increase in DSE with no change in DSI in glutamate treated slices also
supports our hypothesis that the relative upregulation of CB1 receptors after glutamate
injury is located at glutamatergic terminals and therefore acts to suppress seizure activity.
Our results also support the idea that DSI is not significant in the control of epilepsy. In
our model, it may be that DSE is the more important cannabinoid mediated effect in
acquired epilepsy. DSE in the hippocampus has only been shown to occur with long
depolarizations (Ohno-Shosaku et al., 2002). This sustained depolarization may not be
physiologically relevant under normal conditions, but may be of great importance during
seizures. Our results in both spontaneous and evoked EPSCs point to greater control of
CB1 receptor activation in inhibiting excitatory transmission in a chronic epileptic state.
In addition, studies have shown greater DSI with very short depolarizations (Lafourcade
et al., 2009), indicating that DSI may play a more important modulatory role in normal
cell signaling without modulating pathological conditions such as epilepsy. Thus, the
increase in CB1 receptor expression after the development of epilepsy plays a functional
role in neuroprotection in this model. It has been shown that inducing DSE in
hippocampal tissue is dependent on the sensitivity of the presynaptic neuron to
cannabinoids as well at the duration of postsynaptic depolarization (Ohno-Shosaku et al.,
2002). With extended depolarization, the result of CB1 receptor activation may be a shift
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from DSI to DSE. Therefore, the extended neuronal depolarization of an epileptiform
discharge may cause a greater suppression of glutamate release rather than a suppression
of GABA release (Wallace et al., 2003).
This study provides some important insight into the functional relationship of CB1
receptor expression and physiological activity following the development of acquired
epilepsy. Future studies of this kind are necessary in other in vitro and in vivo models to
truly understand the role of the endocannabinoid system in regulating seizure activity, as
this could have great clinical implications in specifically targeting receptors that control
seizures.

F. Conclusion
The studies presented in this dissertation provide a powerful new model of stroke
acquired epilepsy utilizing an organotypic in vitro system. These studies have thoroughly
demonstrated the utility of organotypic hippocampal slice cultures as a system for
inducing injuries that produce a model of epileptogenesis. We have demonstrated many
similarities between our in vitro model and other in vivo models of acquired epilepsy.
OHSCs provide several advantages over in vivo models in their functionality in highthroughput screening of pharmacological agents in an in-tact tissue model. We have
utilized the OHSC model of stroke acquired epilepsy to further study the molecular and
physiological changes of the endocannabinoid system following epileptogenesis. These
studies add to the growing body of evidence that the endocannabinoid system is able to
efficiently regulate presynaptic inputs onto neurons, acting as a neuromodulatory system
in epilepsy. We have demonstrated that OHSCs specifically upregulate CB1 receptors in
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the stratum radiatum and stratum oriens following a stroke-like injury with glutamate.
We have also demonstrated that the CB1 receptors on glutamatergic terminals are
functional in suppressing excitatory signals to CA3 pyramidal neurons.
Findings from this study have numerous implications for persons with epilepsy. It
continues to support the importance of the endocannabinoid system as an endogenous
mechanism to control neuronal hyperexcitability. Indeed, animal studies have shown CB1
receptor antagonism is detrimental in epileptic rats (Wallace et al., 2003). This
hypothesis was recently supported with clinical evidence utilizing the CB1 inverse
agonist Rimonabant (SR141716A). Rimonabant was marketed in Europe from 2006-2008
for the treatment of obesity. A case report of the drug chronicled a 52 year old man who
had suffered two seizures as a child, but had been seizure free and without antiepileptic
drugs for more than 20 years. After starting treatment with Rimonabant for weight loss,
the man began suffering from nocturnal partial seizures that disappeared upon cessation
of Rimonabant (Braakman et al., 2009). This further supports evidence from animal
models and our OHSC model of epilepsy that the distribution of CB1 receptors in
epilepsy acts to control neuronal hyperexcitability.
Results from these studies continue to support the hypothesis that development of
epilepsy induces a compensatory upregulation of CB1 receptors on glutamatergic
terminals to preferentially suppress excessive neuronal excitatory signaling. This data
implies that future therapeutic targets for the control of epilepsy lie in the CB1 receptors
of glutamatergic terminals. The recent development of FAAH and MAGL inhibitors
provides a unique tool to study the effects of increasing concentrations of endogenously
produced CB1 agonists rather than administering exogenous agonists. However, a recent
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study has found that tolerance and physical dependence develops in mice after chronic
treatment with the MAGL inhibitor JZL 184, but not the FAAH inhibitor PF-3845
(Schlosburg et al., 2010). Acute application of JZL 184 enhances DSE, while inhibition
of FAAH has no effects on DSE(Pan et al., 2009). These studies provide further evidence
that 2-AG is the endocannabinoid responsible for DSI and DSE, but they raise questions
of the utility of chronic treatment with MAGL inhibitors. However, these compounds
have yet to be fully tested in seizure models, where we know the CB1 receptors display a
different functional distribution. A different FAAH inhibitor, AM374, has been shown to
decrease seizure severity and cell damage in kainic acid induced seizures. Further
evidence in animal models supports the antiepileptic effects of anandamide (Wallace et
al., 2002), while a recent study in humans found decreased anandamide levels in patients
with temporal lobe epilepsy (Romigi et al., 2010). In contrast, FAAH knockout animals
have been shown to have enhanced seizures in response to kainic acid (Clement et al.,
2003). This conflicting data deserves greater research to delineate the role of each of the
endocannabinoids in modulating seizure activity. The OHSC model of stroke-induced
acquired epilepsy provides an efficient model to study these complex interactions and has
the capacity to provide great insight into the utility of pharmacological manipulation of
the endocannabinoid system in epilepsy.
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